







Investigating Mechanisms through which Calorie 
Restriction and Pharmacological Mimetics Attenuates 






Senior Honors Thesis 
Department of Nutrition 
Gillings School of Global Public Health 
University of North Carolina at Chapel Hill 
 
 






         Approved by:  
 
 
                                                           _____________________________________ 




                                                           _____________________________________ 





Background: Among US women, basal-like and triple-negative breast cancer subtypes confer 
worse patient survival due to a lack of targetable receptors. Furthermore, obesity is a major 
public health concern in the US with a prevalence of 41.9% in women aged >20. Obesity 
significantly increases the risk of developing and dying from breast cancer by impacting its 
initiation, progression, and metastasis through IGF-1/Akt/mTOR, and inflammation/immune 
signaling pathways. A promising area in nutrition and cancer research is caloric restriction (CR) 
which has been shown to reduce tumor incidence and progression; however, in a nutrient-starved 
state, cancer cells can break down damaged cellular components to maintain viability through 
autophagy. This study aimed to determine the effectivity of CR regimens reversing the adverse 
impact of obesity on the tumor transcriptional profile. We also conducted in vitro studies to test 
the hypothesis that the addition of an autophagy inhibitor would enhance the anticancer activity 
of pharmacological agents which mimic the metabolic reprogramming effects of CR. 
 
Methods: Young mice were placed on a diet-induced obesity (DIO) regimen for 15 weeks 
before being randomized to remain on DIO ad libitum or change to a low-fat control diet ad 
libitum, a 30% chronic calorie-restricted diet (CCR), or an intermittent calorie-restricted (ICR) 
diet for 10 weeks. Mice were orthotopically transplanted with E0771 (basal-like subtype) breast 
cancer cells and tumors were excised at endpoint. Differential tumor gene expression was 
profiled via Affymetrix microarray and analyzed using transcriptome analysis console and Gene 
Set Enrichment Analysis. In-vitro, E0771 and MDA-MB-468 cells (triple-negative subtype) were 
treated with BMS-754807, a dual IGF-1R/INSR inhibitor, and Everolimus, an mTORC1 
inhibitor, separately and in combination with the autophagy inhibitor, chloroquine (CQ). Cell 
viability was determined using MTT assays, and target inhibition and potential induction of 
autophagy was investigated using Western blots. The potential synergistic effect of Everolimus 
or BMS-754807 in combination with CQ was analyzed using SynergyFinder software. 
 
Results: Calorie-restricted mice displayed reduced tumor mass compared to DIO and control 
mice. Gene expression analyses demonstrated that tumors from DIO mice have enrichment of 
gene sets related to tumor progression (e.g. epithelial-to-mesenchymal transition, hypoxia) and 
underrepresentation of immune-related antitumor gene markers (e.g. interferon response 
alpha/gamma, Cd8 T-cells). Both CR interventions reversed DIO-related enrichment of pro-
tumorigenic and underrepresentation of immune signaling gene sets. In E0771s and MDA-MB-
468s, this study confirmed the target inhibition of Everolimus on mTOR. From combination 
treatments, it was found that BMS-754807 + CQ synergistically inhibited E0771 viability and 
Everolimus + CQ synergistically inhibited MDA-MB-468 viability. 
 
Conclusion: This study confirms that obesity induces gene expression alterations within the 
tumor microenvironment that support tumor growth. Our results demonstrate that weight loss by 
CCR and ICR interventions effectively reverse pro-tumorigenic effects of obesity, reducing 
angiogenic signaling and increasing the activation/abundance of immune cell markers within the 
tumor microenvironment. Our findings show that pharmacological metabolic-reprogramming 
interventions, mimicking CR and autophagy inhibition as treatments for triple-negative/basal-
like BC, has the potential for combination treatments to work synergistically against cell growth. 
Alyssa Ho 
 3 
Table of Contents 
Introduction ................................................................................................................................ 5 
Basal-Like and Triple-Negative Breast Cancer Subtypes Confer Worse Patient Survival ........ 5 
Obesity Adversely Affects Breast Cancer Outcomes ............................................................... 6 
Nutrient Restrictive Interventions and Autophagy ................................................................... 8 
Autophagy Inhibition as an Adjuvant Therapy ........................................................................ 9 
Goals and Hypotheses ............................................................................................................... 10 
Methods.................................................................................................................................... 11 
Results ...................................................................................................................................... 15 
Conclusion ............................................................................................................................... 35 
References Cited ....................................................................................................................... 36 

























I would like to thank Dr. Stephen Hursting for providing me the opportunity to conduct 
research in his lab for the past two years surrounded by fellow scientists I am proud to work with 
every day. I am especially grateful for the guidance and support of Laura Smith, Dr. Alyssa 
Cozzo and Dr. Michael Coleman who have been patient in teaching me every research technique 
discussed in this thesis and invested countless hours of their time in my development as an 
undergraduate researcher. I would also like to thank Honors Carolina and the William and Ida 
W. Taylor Honors Mentor Fellowship for granting me the funding necessary to continue research 
through the Summer Research Undergraduate Fellowship (SURF) program. Lastly, I would like 
to thank my family and friends for their unwavering support in everything I do and for 

















Basal-Like and Triple-Negative Breast Cancer Subtypes Confer Worse Patient Survival  
Among women in the United States, breast cancer is the most prevalent cancer and 
second-leading cause of cancer-related death1. In 2020, it is projected that there will be over 
275,000 new breast cancer cases diagnosed in US women, and an estimated 42,170 deaths2. 
Although the five-year relative survival rate of breast cancer patients after primary diagnosis is 
80-90%, survival rates differ based on a tumor’s molecular characteristics3. Using DNA and 
gene expression, breast tumors are classified as luminal A, luminal B, HER2 enriched, and basal-
like subtypes based on expression of hormone receptors and human epidermal growth factor 
receptor 2 (HER2)4. While the five-year relative survival rates of luminal A, luminal B, and 
HER2-enriched subtypes are 92%, 89%, and 83% respectively, the five-year relative survival 
rates of basal-like breast cancer is only 77%5. 
The basal-like breast cancer subtype was identified through gene expression analysis as 
breast tumors that highly expressed genes in the basal layer of the mammary gland and is 
associated with poor prognosis due to its ability to relapse quickly6. Because gene expression 
analysis is both expensive and time-consuming, immunohistochemical staining is used clinically 
to classify breast cancers which has led to the triple-negative breast cancer (TNBC) subtype7. 
Although basal-like and triple-negative breast cancers are oftentimes used interchangeably, they 
are not biologically synonymous and it is thought that approximately 77% of basal-like cancers 
are triple-negative7. TNBC comprises 15-20% of all breast cancer cases and is associated with 
elevated rates of cancer recurrence, metastasis, and a decreased five-year survival rate compared 
to non-TNBC subtypes7,8,9. There are several age and race-related disparities associated with 
TNBC as it is typically diagnosed in younger premenopausal women and is diagnosed at a higher 
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rate in black and Hispanic women compared to white women10. TNBCs lack expression of 
estrogen receptors, progesterone receptors, and excessive human-epidermal growth factor 
receptor 2 (HER2), all of which can be targeted therapeutically in other molecular subtypes 
expressing these receptors7,8,9. As a result, there is a lack of targeted therapies for TNBC patients 
whose traditional treatment approaches are cytotoxic chemotherapy and surgery9,11. Thus, there 
is a need to find novel approaches to treat TNBC patients that are less damaging and toxic.  
TNBCs are challenging to treat for various reasons. Generally, they are characterized by 
larger mean tumor size and higher-grade tumors9,12. TNBC is also a clinically heterogeneous 
subtype of breast cancer, and there is continuing research on effective targets of TNBC-
associated signaling pathways and molecular markers13. One potential target is the 
PI3K/AKT/mTOR pathway as it is frequently dysregulated in TNBC, and overactivation of 
downstream mTOR is associated with worse prognosis in TNBC patients9,14,15. PI3K/AKT 
signaling is initiated following the activation of various receptor tyrosine kinases9,14,15. One 
receptor tyrosine kinase in particular that may be a potential target for TNBC therapy is insulin-
like growth factor receptor (IGF-1R)13,16. When IGF-1R binds to its ligand, insulin-like growth 
factor 1 (IGF-1), the activation of the IGF-1/IGF-1R complex promotes cell proliferation, 
metastasis, and survival16,17. Thus, the decreased activation of mTOR and reduced active form of 
IGF-1 may prove to be useful targets in TNBC treatment.  
Obesity Adversely Affects Breast Cancer Outcomes 
Obesity is a major public health concern in the United States, as greater than 35% of the 
US population are obese18. Obesity significantly increases both the risk of development and 
eventual mortality from multiple chronic diseases including breast cancer19. Obesity is associated 
with worse outcomes in patients bearing basal-like and TNBCs19. There are several mechanisms 
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by which obesity is believed to impact BC initiation, progression, and metastasis including: 
increased stimulation of the PI3K/Akt/mTOR signaling pathway, increased bioavailability of 
IGF-1, an increased inflammatory state, and immune cell switching. 
It is well established that the Akt/mTOR signaling pathway is critical to breast cancer 
development as it is highly involved in cell growth, proliferation, and survival and its 
dysregulation leads to several pathological conditions negatively associated with health including 
obesity where in the obese state, mTOR is overactivated20. It has been shown that 
mechanistically inhibiting the PI3K/Akt/mTOR pathway suppresses the adipocyte-mediated 
growth and metastasis of BC cells21. Given that activation of the Akt/mTOR signaling pathway 
is associated with poor prognosis in BC patients, elevated insulin signaling via Akt/mTOR may 
contribute to negative outcomes in obese patients19,20,21. Additionally, obesity increases 
bioavailability of insulin-like growth factor 1 (IGF-1), which as previously stated is a hormone 
critical to tumor growth in cancer cells, as it blocks apoptosis and increased cell 
proliferation16,17,22. IGF-1 receptor (IGF-1R) activity has been shown to be upregulated in basal-
like and TNBC, indicating that IGF-1/IGF-1R activity may contribute to BC development and 
progression23. Obesity leads to an inflammatory state associated with greater numbers of tissue 
inflammatory cytokines that result in more aggressive BC progression19,24,25. Finally, increasing 
evidence suggests that the obese state leads to immune cell switching related to more aggressive 
BC biology19,24. In the lean state, M2 macrophages and T-cells help dampen the inflammatory 
state; however, in the obese state, M1 macrophages are recruited into adipose tissue and produce 




Nutrient Restrictive Interventions and Autophagy 
A promising area in nutrition and cancer research, with the potential to improve cancer 
outcomes, is dietary modification. For example, interventions which reduce caloric intake such 
as caloric restriction (CR) has been shown to reduce tumor incidence, progression, and 
sensitization to some chemotherapeutic agents in preclinical TNBC murine models26,27. Proposed 
mechanisms underlying the beneficial effects of nutrient restrictive interventions include a 
reduction in the active form of IGF-1 and a decreased activation of the PI3K/ mTOR pathway26. 
While dietary interventions have shown promise for improving cancer outcomes in 
murine models, translating these approaches to humans has proven difficult. Major issues include 
a low tolerance of extreme diets (feasibility) and concerns about safe use of these interventions 
in cancer patients28. Additionally, in response to the decrease in external nutrients and pro-
growth signals (such as IGF-1 signaling) during a fasting or CR state, mTOR activity decreases, 
and cancer cells can generate energy by breaking down damaged cellular components to 
maintain homeostasis and viability through the process known as autophagy29. There are three 
main types of autophagy: microautophagy, chaperone-mediated autophagy, and 
macroautophagy30,31,32. This thesis will focus on the most well-studied form of autophagy, 
macroautophagy (hereafter referred to as autophagy), in which cellular contents are sequestered 
in double-membrane vesicles known as autophagosomes and then delivered to the lysosome for 
degradation30,31,32. In cancer, autophagy’s role is complex and its effects vary depending on the 
stage of cancer progression33. In early stages, autophagy is considered to suppress cancer 
progression; however, in later stages, autophagy can provide benefit to established tumor cells 
fighting for survival in nutrient-poor conditions by promoting tumor growth and, in some cases, 
metastasis which is the primary cause of cancer-related death33,34,35.  
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Autophagy Inhibition as an Adjuvant Therapy 
 While autophagy has complex roles in cancer biology, it has been examined as a potential 
target in cancer cells. Early studies investigating autophagy and cancer focused on the 
knockdown of key autophagy-related genes including: Atg5, Atg7, Atg12, and Becn1 which are 
used to disrupt autophagy and investigate the role of single genes on the autophagy 
process36,37,38,39. In the nutrient-starved state where there is an increased dependence on 
autophagy, studies have investigated the potential for exploiting this increase in autophagy to 
improve the efficacy of autophagy inhibitors and existing chemotherapies22,29. In an in-vivo study 
conducted by Lashinger et. al, combined calorie restriction and autophagy inhibition resulted in 
greater tumor suppression than either CR or autophagy inhibition alone22. 
While early studied focused on the knockout of autophagy-related genes, 
pharmacological inhibition of autophagy has also been investigated as a potential adjuvant 
therapy29,40,41,42. One commonly-used pharmacological inhibitor of autophagy is chloroquine 
(CQ), an FDA-approved anti-malarial drug29,40,41,42. Although the exact mechanism by which CQ 
inhibits autophagy has yet to be fully elucidated, CQ mainly inhibits autophagy by preventing 
autophagosome fusion with lysosomes29,40,42,43. For our study, we hypothesized that the 
inhibition of autophagy under conditions in which autophagy is induced, such as calorie 
restriction, will reduce BC progression. There are several pharmacological agents which can act 
as metabolic reprogramming interventions (MRIs) in the cell, mimicking a nutrient-restricted 
state leading to the induction of autophagy44,45. These include: Everolimus which targets 
mTORC1 signaling and BMS-754807 which targets both IGF-1R and insulin receptor (INSR) 
signaling44,45,46. Understanding the separate and combined effects of autophagy-inducing MRIs 
and autophagy inhibition is important to finding more targeted therapies for BC progression. 
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Goals and Hypotheses 
 
The primary goal of this project is to identify underlying mechanisms through which 
calorie restriction and pharmacological mimetics attenuates breast cancer progression. 
Aim 1. Determine whether CR regimens reverse the adverse effects of obesity on the 
tumor transcriptional profile.  Hypothesis: Tumors from formerly obese mice that were placed 
on either chronic or intermittent CR diets will display underrepresentation for gene sets related to 
IGF-1 and mTOR signaling and enrichment for gene sets related to inflammation and immune 
signaling, compared to obese mice. Approach: Gene expression will be measured in tumors and 
analyzed using transcriptome analysis console, Gene Set Enrichment Analysis and gene sets 
related to IGF-1, mTOR signaling, and inflammation.   
Aim 2. Test whether pharmacological mimetics of CR which inhibit mTOR and 
IGF-1R and inhibit autophagy will further enhance anti-cancer effects of autophagy 
inhibition alone. Hypothesis: The combination treatment of Everolimus and BMS-754807 with 
the autophagy inhibitor, chloroquine, in triple-negative/basal-like BC cells will result in 
enhanced anti-cancer effects. Approach: E0771 cells, a form of basal-like BC and MDA-MB-
468 cells, a form of triple-negative BC will be treated with BMS-754807, a dual IGF-1R/INSR 
inhibitor, and Everolimus, an mTORC1 inhibitor separately and in combination with the FDA-
approved autophagy inhibitor, chloroquine (CQ), to examine the combined effects of autophagy-
inducing metabolic reprogramming interventions with autophagy inhibition. After treatment with 
these pharmacological agents, BC cell viability will be determined using MTT assays. Target 
inhibition and potential induction of autophagy will be confirmed via Western Immunoblots. The 
potential synergistic effect of the autophagy-inducing pharmacological agents with the 




Animal Study Design 
 Animal study procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of North Carolina at Chapel Hill. Female C57BL/6 mice 
(n=100) were purchased, allowed to acclimate, and then randomized to receive either a low-fat, 
control (n=20, 10% kcal from fat) or high-fat, diet-induced obesity (n=80, 60% kcal from fat) 
regimen ad libitum. Control and DIO diets were supplied by Research Diets, Inc. (#D12450J and 
#D12492, respectively). Following 15 weeks on diet, DIO diet mice were randomized to either 
1) remain on DIO ad libitum or change to 2) the low-fat control diet ad libitum (LF), 3) a 30% 
chronic calorie-restricted diet (CCR) or 4) an intermittent calorie restricted (ICR) diet. The ICR 
diet, which is modeled after the intermittent energy regimen implemented by Michelle Harvie 
and colleagues, consists of 70% CR high-protein diet 2 non-consecutive days/week followed by 
a 13% calorie-restricted (CR) diet the remaining 5 days/week47. Throughout the experiment, all 
mice were housed 2 per cage and mice on a calorie-restricted diet were separated when 
consuming their daily food pellet. After 10 weeks on new diets, all mice were orthotopically 
implanted with E0771 mammary breast cancer cells (3.5 x 104 cells). Using digital calipers to 
monitor tumor growth, all mice were monitored twice a week until tumor endpoint was reached, 
defined by 1 mouse having a tumor 1.5 cm in diameter. At tumor endpoint, the mice were 
sacrificed by carbon dioxide euthanasia and cervical dislocation, and tumors were excised, 
weighed, and collected for subsequent analysis. 
RNA Profiling, Transcriptome Analysis Console, and Gene Set Enrichment Analysis 
 Flash frozen tumors were dissociated in TRIzol Reagent (Sigma-Aldrich). Chloroform 
separation was performed and RNA extracted from resultant aqueous phase using RNeasy 
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Miniprep Kit (Quiagen), according manufacturer’s protocol. RNA purity and quality will be 
determined using NanoDrop spectrophotometer (ThermoFisher) and RNA ScreenTape (Agilent), 
respectively. Gene expression will be profiled using Gene ChipTM Mouse Genome 430 2.0 arrays 
(Affymetrix) in collaboration with the Functional Genomics Core at UNC, according to the 
manufacturer’s protocol.  
Collected gene expression data was analyzed using Transcriptome Analysis Console (TAC) 
which allows differential expression analysis and generates lists of differentially expressed 
genes. Analysis was performed across the following comparisons: DIO vs. control, DIO vs. LF, 
DIO vs. high-carbohydrate calorie restriction (HCCR), and DIO vs. intermittent calorie 
restriction (ICR). Differentially expressed genes were defined as having a gene-level fold change 
of <-1.5 and >1.5 and FDR q-value <0.05.  
Pair-wise pathway enrichment was also analyzed using Gene Set Enrichment Analysis 
(GSEA) and Molecular Signature Database’s Hallmark gene sets, which represent genes 
coordinately altered in broad biological processes and signaling pathways.49 Analysis was 
performed across the same comparisons as described with the TAC differential expression 
analysis. GSEA analysis produces a normalized enrichment score (NES) which reflects the 
strength of a gene sets enrichment in one phenotype verses another. GSEA calculates a false-
discovery rate (FDR) to estimate the probability that the enrichment of a gene set is a false 
positive.50 For analyses conducted, only enriched gene sets with an FDR of less than 0.05 was 
considered significant. Following GSEA, leading edge analysis was performed on gene sets of 






Murine E0771 (basal-like BC subtype) and human-derived MDA-MB-468 cells (triple-
negative BC subtype), both models of basal-like breast cancer were maintained in DMEM 
medium supplemented with 10% Fetal Bovine Serum (FBS) and 5mg/mL L-Glutamine51,52.  
MTT Assay 
To measure cell proliferation over a 72-hour period, E0771 and MDA-MB-468 cells were 
seeded in a 96-well plate (1.5 x 103 cells/well and 1.0 x 104 cells/well respectively). After 24 
hours, cells were treated with one of two metabolic reprogramming interventions (MRI): 1) 
Everolimus, which targets mTORC1 signaling or 2) BMS-754807, a dual IGF1R/insulin receptor 
inhibitor44,46. Following a 24-hour incubation with the MRI, cells were treated with the same 
MRI either alone or in combination with 15 µM or 20 µM chloroquine for another 24-48 hours. 
Following, media was removed and E0771 and MDA-MB-468 cells were treated with 3-(4,5-
demethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (0.5mg/ml in media) for 1.5 and 2 hours 
respectively. Media was aspirated and replaced with dimethyl sulfoxide (DMSO). Plates were 
incubated at RT on a plate shaker for 5 minutes, and then absorbance measured at 570 and 690 
nm using Cytation 3 Cell Imaging reader (BioTek). 
Protein Extraction and Western Immunoblots 
E0771 and MDA-MB-468 cells were seeded in 6cm plates at appropriate densities to 
achieve 70% confluency after 24 hours. Following, cells were treated with low-glucose (1g/L) 
DMEM containing either Everolimus (30 nM and 15 nM for E0771 and MDA-MB-468 
respectively) or BMS-754807 (1 uM for both), alone or in combination with chloroquine (20 uM 
for both). After treatment for 4 hours, cells were lysed with radioimmunoprecipitation (RIPA) 
buffer supplemented with protease inhibitor cocktail (Sigma Aldrich). Cells were then scraped 
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from plates, incubated on ice for 20 minutes, and centrifuged at 14,000 rpm for 15 minutes at 
4°C. The supernatant containing protein was collected, and a Bradford Assay was performed to 
determine protein concentration using a Bradford protein quantification reagent (BioRad). Equal 
concentrations of protein were added to solution containing 5X Loading Buffer (BioRad) and 5% 
B-mercaptoethanol. Protein was then separated via SDS-PAGE, and transferred to PVDF 
membrane (BioRad). Membranes were blocked with 5% bovine serum albumin (BSA) in Tris 
Buffered Saline with 0.1% Tween (TBST) for 1 hour before being incubated overnight at 4°C 
with primary antibody. After washing with TBST, membranes were blocked in secondary anti-
mouse or anti-rabbit antibody (ThermoFisher) for 1 hour at room temperature. Excess secondary 
antibody was removed by TBST washes. Antibody binding was detected using 

















I. Chronic and intermittent calorie restriction reduces BC progression in vivo 
Generation of control, obese, and calorie-restricted phenotypes 
To test whether weight loss by calorie restriction interventions would be more efficacious 
than a low-fat diet, provided ad libitum, in reversing obesity-related acceleration of BC tumor 
growth, diet-induced obese (DIO) mice were placed on either a low-fat control diet, 30% CCR, 
or ICR diet for 10 weeks. Following, mice were orthotopically injected into the mammary 
adipose with E0771 BC cells and tumor growth monitored. 
At tumor endpoint, mice placed on the DIO diet had significantly higher body mass 
relative to normal weight mice fed a control diet (p<0.0001) (Figure 1A, 1B). Additionally, the 
study confirmed that both CCR and ICR diets reversed excess body weight induced by the DIO 
diet and returned mice placed on calorie-restricted diets to weight levels at or below those 
observed in the control mice (p<0.001 for all) (Figure 1A).  
Calorie restriction reduces tumor progression 
 As anticipated, DIO mice had significantly greater tumor mass compared to control 
(p<0.0001) (Figure 1C). DIO mice placed on the low-fat control diet, herein referred to as LF, 
exhibited no difference in tumor mass compared to DIO (Figure 1C). We also noted no 
difference in tumor mass between LF and control mice suggesting that LF may have an 
intermediate level of tumor growth compared to DIO and controls; however, another study with 
increased sample size would be needed to test this hypothesis. In contrast, DIO mice placed on 
the CCR diet and ICR diet, had reduced tumor mass compared to both DIO and control groups 








Figure 1. Diet-induced obesity drives primary tumor growth.  
Mice placed on the DIO diet had significantly higher body mass relative to normal weight mice fed a control diet 
(p<0.0001). CCR and ICR diets reversed excess body weight induced by the DIO diet and returned calorie-restricted 
mice to weight levels at or below those of control mice (p<0.001 for all). (1A, 1B). DIO mice had significantly 
greater tumor mass compared to control (p<0.0001) (1C). Mice on the LF control diet exhibited no difference in 
tumor mass compared to DIO and there was no difference in tumor mass between LF and control mice (1C). DIO 
mice placed on the CCR diet and ICR diet, had reduced tumor mass compared to both DIO and control groups 
(p<0.05 for both) (1C). 
 
II. Diet-induced obesity increases gene expression markers of tumor aggression 
Obesity increases gene expression markers of tumor aggression 
 
To determine how weight loss by the various diet interventions altered signaling within 
the tumor microenvironment, we examined gene expression patterns within collected tumor 
samples of obese, formerly obese and calorie-restricted mice. Whole tumor RNA was profiled 
via microarray and analyzed using Transcriptome Analysis Console (TAC) software. Principal 
component analysis (PCA) demonstrated that CCR and ICR tumors tended to cluster with one 
another while control, DIO and LF mice clustered together (Figure 2).  This indicates that gene 
expression alterations induced by both calorie restrictive regimens are more similar to one 








Figure 2. Calorie-restricted mice show 
similar gene expression. 
Principle component analysis (PCA) 
mapping plot analyzed with TAC showing 
the cluster of samples associated with the 
different diet groups: Control, DIO, FOb-
LF, HCCR, and IER. The HCCR and ICR 
groups are clustered closer together, 








To identify gene-level changes induced by obesity and each of the dietary interventions 
on the tumor microenvironment, we determined differential gene expression across the following 
comparisons: DIO vs. Control, DIO vs. LF, DIO vs. HCCR, and DIO vs. ICR. Differentially 
expressed genes were defined as having a gene-level fold change of <-1.5 or >1.5 and FDR q-
value <0.05 (Figure 3). 
 
Figure 3. Calorie-restricted mice 
show increased levels of differential 
gene expression. 
Tumoral gene expression analyzed 
with TAC software was utilized to 
generate an analysis summary view 
with gene-level fold change 
parameters of <-1.5 or >1.5. 
Differential expressed genes 
upregulated or downregulated 
determined by FDR q-value <0.05. 
 
When comparing DIO to control, there were 5 differentially expressed genes, 2 
upregulated and 3 downregulated (Figure 4A, Appendix A: Table 3). In agreement with 
increased tumor growth in DIO mice, tissue inhibitor of metalloproteinase 2 (TIMP-2), was 
found to be upregulated in DIO tumors. TIMPs are multifunctional and it is well known that 
TIMP-2 blocks matrix metalloproteinases (MMPs) to prevent metastasis53. However, studies 
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suggest that in breast cancer, TIMP-2 acts independently of its role in inhibiting MMP activity, 
and increased expression of TIMP-2 has been shown to correlate with increased BC progression 
and shortened disease-free survival53. In contrast, genes downregulated in DIO tumors included 
tumor necrosis factor (ligand). In agreement with increased tumor size in DIO mice, tumor 
necrosis factor ligand, which encodes a protein involved in the induction of apoptosis in tumor 
cells, showed decreased expression54. 
Interestingly, we observed no differentially expressed genes when comparing DIO to LF 
mice (Figure 4B). This supports conclusions drawn from the tumor data in which weight loss by 
LF diet did not effectively reverse obesity-related tumor progression.  
When comparing DIO vs. HCCR groups, there were 45 differentially expressed genes 
that were upregulated and 106 that were downregulated in DIO vs. HCCR (Figure 4C, Appendix 
A: Table 4). Genes upregulated in DIO vs. HCCR have been linked to increased tumor 
progression including: gene regulated by estrogen in breast cancer protein (GREB1), and GLI-
Kruppel family member (Gli2). It has been shown that knockdown of GREB1 inhibits hormone-
driven BC proliferation; thus, in agreement with increased tumor size in the DIO mice, GREB1 
was upregulated in DIO mice55. Gli2 encodes a transcription factor whose target genes are 
involved in BC proliferation, survival, and metastasis; thus, its upregulation in DIO mice acts in 
agreement with the observed increased tumor size in DIO mice56,57. 
Many of the genes downregulated in DIO vs. HCCR are immune signaling molecules 
(e.g. granzymes, killer cell lectin-like receptors, perforins, and chemokines). In agreement with 
increased tumor growth in DIO mice, killer cell lectin-like receptor 1 (KLRC1) was 
downregulated in DIO tumors. KLRCs are expressed on natural killer cells and help activate 
signals which contribute to apoptosis of tumor cells58. Decreased KLRC1 expression has been 
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shown in invasive BC compared to adjacent normal tissue59. Granzymes and perforins are 
cytotoxic molecules, which are released by cytotoxic lymphocytes and natural killer cells, that 
can induce apoptosis in nearby tumor cells60. In the obese state, genes encoding granzymes such 
as granzyme B are downregulated, and granzyme B and perforin expression have been shown to 
play a role in suppressing metastasis of BC cells61,62. Thus, in agreement with increased tumor 
size in the DIO mice, granzyme B and perforin 1 were downregulated in DIO tumors. 
Additionally, Cd3 and Cd8 were downregulated in DIO tumors, both of which are markers of 
cytotoxic T cells which release granzymes and perforins63. Chemokines play an important role in 
tumor growth and progression by inducing proliferation and blocking apoptosis of cancer cells64. 
The chemokine receptor CXCR3 has been shown to bind to Chemokine (C-X-C motif) ligand 9 
(CXCL9) and act as a tumor suppressor in BC cells65. In agreement with increased tumor size in 
the DIO mice, CXCL9 was downregulated in the DIO mice. 
ICR diet had the most profound transcriptional effects when compared to DIO as there 
were 366 genes upregulated and 308 downregulated in DIO vs. ICR (Figure 4D, Appendix A: 
Table 5). In agreement with increased tumor size in DIO mice, two genes: insulin-like growth 
factor binding protein 3 (IGFBP3) and interleukin 33 (IL33) were upregulated in DIO tumors. 
IGFBP3 overexpression has been shown to lead to enhanced BC cell growth in-vitro suggesting 
that IGFBP3 is involved in tumorigenesis66,67. It has been suggested that IL33 expression 
promotes BC progression by reducing cellular innate anti-tumor immunity68. In agreement with 
increased tumor size in DIO mice, some of the genes downregulated in DIO vs. ICR were ones 








Figure 4. Calorie-restricted mice show most 
profound levels of differential gene 
expression.  
Tumoral gene expression was analyzed with 
TAC to generate volcano plot graphs to 
illustrate positively or negatively enriched 
genes in DIO vs. Control (A), DIO vs. FOb-LF 
(B), DIO vs. HCCR (C) and DIO vs. ICR (D) 
groups determined by FDR q-value <0.05. 
Plots displaying significance vs. fold-change 
on y- and x-axes, respectively. Green TCs are 
downregulated in DIO vs. diet intervention 
group while the red TCs are upregulated in 







III. DIO tumors are commonly enriched for genes related to tumor aggression and CR 
interventions effectively reverse protumorigenic effects of obesity 
 
Diet-induced obesity leads to enrichment of gene sets related to tumor progression 
 
We next utilized Gene Set Enrichment Analysis (GSEA) to examine whether gene-level 
transcriptional changes translated to enrichment of certain signaling pathways in tumors. GSEA 
was conducted using Hallmark gene sets, which describe transcriptional changes that occur 
across specific biological pathways and processes including PI3K/AKT/MTOR signaling and 
inflammatory response. Analyses were performed across the same comparisons as described 
above and significantly enriched gene sets were defined by FDR <0.05.   
DIO tumors were enriched for 11 gene sets relative to control (Table 1) involved in 
developmental, metabolic, and cell signaling (Table 1). In agreement with increased tumor size 
in DIO mice and reduced tumor size in CR mice, epithelial-to-mesenchymal (EMT) transition 
was found to be positively enriched in DIO tumors and reversed by both CR interventions. In 
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BC, EMT promotes tumor progression, invasion, and metastasis69. Similarly, hypoxia was found 
to be positively enriched in DIO tumors and reversed by both CR interventions. In the tumor 
microenvironment, hypoxia is associated with an increased risk of BC metastasis and mortality70.  
Table 1. Hallmark gene sets commonly enriched in DIO tumors. 
Tumoral gene expression was analyzed using GSEA and hallmark gene sets. Gene sets positively enriched in DIO 
vs. Control, DIO vs. FOb-LR, DIO vs. FOb-HCCR, and DIO vs. ICR as determined by FDR q-value <0.05.  
Tumors from DIO mice were commonly enriched for gene sets related to tumor aggression, some of which were 
reversed by CCR and/or ICR interventions. 
 
Diet-induced obesity leads to negative enrichment of gene sets related to immune-signaling 
 
 Next, we examined gene sets which were downregulated in DIO vs. Control, DIO vs. LF, 
DIO vs. FOb-HCCR, and DIO vs. FOb-IER (Table 2). DIO tumors were downregulated for 10 
gene sets relative to control related to immune signaling and cell cycle regulation (Table 2). In 
agreement with increased tumor size in DIO mice, interferon alpha response (IFN𝛼), interferon 
gamma response (IFN𝛾) were found to be downregulated in DIO tumors. In the obese state, 
chronic inflammation results in an “exhausted” state with reduced T cell proliferation and 
promotes other immunosuppressive cell types71. These alterations ultimately contribute to an 
immunosuppressive tumor microenvironment71. Both IFN𝛼	and	IFN𝛾	serve as important 
antitumor immune mediators72. Interestingly, although we hypothesized that mTOR-related 
NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val
HALLMARK_ADIPOGENESIS 2.15 0.00E+00 --- --- 1.56 2.01E-02 --- ---
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 1.63 1.88E-02 --- --- 2.37 0.00E+00 2.33 0.00E+00
HALLMARK_MYOGENESIS --- --- 2.95 0.00E+00 2.84 0.00E+00 3.17 0.00E+00
HALLMARK_ANGIOGENESIS 1.57 2.32E-02 --- --- 1.53 2.13E-02 --- ---
HALLMARK_FATTY_ACID_METABOLISM 1.69 1.50E-02 --- --- --- --- --- ---
HALLMARK_GLYCOLYSIS 1.61 1.80E-02 --- --- --- --- 1.55 4.02E-02
HALLMARK_XENOBIOTIC_METABOLISM 1.56 2.29E-02 --- --- --- --- --- ---
HALLMARK_ESTROGEN_RESPONSE_EARLY 1.53 2.28E-02 --- --- --- --- --- ---
HALLMARK_ANDROGEN_RESPONSE 1.44 3.66E-02 --- --- --- --- --- ---
HALLMARK_UV_RESPONSE_DN 1.75 8.44E-03 --- --- 1.65 7.82E-03 --- ---
HALLMARK_KRAS_SIGNALING_DN --- --- 1.78 8.79E-03 1.66 8.36E-03 1.54 3.75E-02
HALLMARK_NOTCH_SIGNALING --- --- --- --- 1.56 1.90E-02 1.67 1.46E-02
HALLMARK_APICAL_JUNCTION --- --- --- --- 1.61 1.43E-02 --- ---
HALLMARK_HYPOXIA 1.53 2.47E-02 --- --- 1.71 6.90E-03 1.96 0.00E+00





















DIO vs Control DIO vs FOb-LF DIO vs FOb-HCCR DIO vs FOb-ICR
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signaling would be upregulated in DIO vs. FOb-HCCR groups due to the increased activation of 
the PI3K/Akt/mTOR pathway in the obese state, we found that mTOR-related signaling was 
downregulated in obesity vs. chronic CR21. Due to this unexpected result, hallmark gene sets 
related to mTOR signaling was chosen for further validation. 
Table 2. Hallmark gene sets commonly downregulated in DIO tumors. 
Tumoral gene expression was analyzed using GSEA and hallmark gene sets. Gene sets downregulated in DIO vs. 
Control, DIO vs. FOb-LR, DIO vs. FOb-HCCR, and DIO vs. ICR as determined by FDR q-value <0.05. Tumors 
from DIO mice were negatively enriched for markers of antitumor immunity, some of which were reversed by CCR 
and ICR interventions. 
 
Because we hypothesized that mTOR signaling would drive changes in the tumor 
microenvironment in DIO vs. CR mice, mTORC and PI3K/Akt/mTOR signaling was chosen for 
further validation with leading edge analysis for DIO vs. FOb-HCCR. Leading edge is used to 
identify the genes that significantly contributed to the NES50. Genes shown to be leading 
contributors to the negative NES in the FOb-HCCR mice compared to DIO were primarily 
immune-related genes involved in BC tumor progression including: Fas ligand (FASLG) and 
LCK proto-ontogene Src family tyrosine kinase (LCK) (Appendix A: Table 6). When the 
FAS/FASLG complex is deregulated, the immune system cannot properly induce apoptosis in 
tumor cells, resulting in BC tumor progression73. LCK is an important signaling molecule in the 
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selection/maturation of T-cells which has been linked to tumor progression74. Two leading edge 
analysis genes were found to be specific to the mTOR and IGF-1 pathways including: vav 
guanine nucleotide exchange factor 3 (VAV3) and ribosomal protein S6 kinase A1 (RPS6KA1). 
When activated, IGF-1R leads to the tyrosine phosphorylation of VAV3 whose overexpression is 
common in BC cells75. Ribosomal S6 kinase has been studied extensively, and it is well-
established that mTORC1 phosphorylates S6 kinase, and the mTORC1-S6K1 complex works to 
result in BC proliferation76. 
IV. Pharmacological mimetics of calorie restriction in vitro induce BC cytotoxicity  
 
Metabolic reprogramming interventions using Everolimus or BMS-754807 have cytotoxic effects 
on triple-negative/basal-like breast cancer cells 
 
To determine whether metabolic reprogramming interventions inhibited triple-
negative/basal-like BC cell growth, we tested the effects of two metabolic reprogramming 
interventions (Everolimus, an mTORC1 inhibitor and BMS-754807, a dual IGF1R/insulin 
receptor (INSR) inhibitor) on tumor cell viability. E0771 and MDA-MB-468 cells were treated 
with either a vehicle control, Everolimus or BMS-754807 for 24 hours and cell viability was 
measured via MTT assay. In E0771 cells, Everolimus treatment did not affect cell viability 
compared to vehicle (Figure 5A). In contrast, BMS-754807 treatment induced significant growth 
inhibition/cytotoxicity at doses ≥1.250 uM (p<0.001 for 0.313 uM, p<0.0001 for all other 
dosages) compared to vehicle (Figure 5B). In MDA-MB-468 cells, treatment with Everolimus 
resulted in significant growth inhibition at doses ≥15.63 nM (p<0.0001 for all) compared to 
vehicle (Figure 5C). BMS-754807 treatment induced significant cytotoxicity at doses ≥0.625 uM 
















Figure 5. Effects of pharmacological agents mimicking calorie restriction on cell viability. 
Following 24 hours of nutrient restriction, E0771 cells are treated with Everolimus at increasing doses of 15.63 nM, 
31.25 nM. 62.5 nM, 125 nM, 250 nM, 500 nM, and 1000 nM (A) or BMS-754807 at increasing doses of 0.313, 0.625, 
1.25, 2.5, 5, 10, and 20 µM (B).  MDA-MB-468 cells were treated with Everolimus (C) and BMS-754807 (D) at the 
same doses as E0771s. Controls for each group were low-glucose DMEM media. An MTT assay was conducted to 
measure % growth inhibition/cytotoxicity. Data presented as mean ± SD with axes x = log(concentration) and y = % 
growth inhibition/cytotoxicity for N=3 experiments. 
 
In E0771 cells, Everolimus treatment did not affect cell viability compared to a vehicle of 
no treatment (Figure 5A). In contrast, BMS-754807 treatment induced significant growth 
inhibition/cytotoxicity at doses ≥1.250 uM (p<0.001 for 0.313 uM, p<0.0001) compared to 
vehicle (Figure 5B). In MDA-MB-468 cells, treatment with Everolimus resulted in significant 
growth inhibition at doses ≥15.63 nM (p<0.0001) compared to vehicle (Figure 5C). BMS-
754807 treatment induced significant cytotoxicity at doses ≥0.625 uM (p<0.0001) compared to 
control levels (Figure 5D). 
Everolimus achieves its target inhibition of mTOR signaling 
 
 To confirm that Everolimus and BMS-754807 treatment reprogrammed the metabolic 
signaling pathways of which they are intended to target and test whether their treatment induced 
Alyssa Ho 
 25 
autophagy, we performed western blot analysis on cell lysates following treatment with MRIs. 
E0771s and MDA-MB-468s were cultured in low-glucose nutrient restricted medias and treated 
with either Everolimus or BMS-754807 alone or in combination with CQ. Then, protein lysates 
were isolated and probed for specific proteins related to mTORC1, IGF-1, and autophagy 
signaling via Western immunoblotting. 
 We hypothesized that treatment of BC cells with Everolimus and BMS would result in 
reduced expression of phosphorylated S6 protein (pS6) which is located downstream of 
mTORC1 and is critical in regulating cellular proliferation. As expected, treatment of MDA-MB-
468 and E0771 cells with Everolimus experienced decreased expression of pS6. However, 
treatment of both cells with BMS-754807 did not result in decreased levels of pS6. BMS-754807 
targets IGF-1R which signals downstream through multiple pathways other than the 
PI3K/Akt/mTOR signal transduction chain such as the MAPK activation pathway77. Thus, it is 
possible that BMS-754807 may be disrupting signaling in pathways other than PI3K/Akt/mTOR 












Figure 6. Confirmation of target inhibition of Everolimus on pS6 levels. 
MDA-MB-468 (A) and E0771 (B) TNBC cells were cultured in low-glucose media overnight and treated with 20 
µM chloroquine (CQ), 1 µM BMS, 15 or 30 nM Everolimus (MDA-MB-468, E0771 respectively), separately or in 
combination for 4 hours and lysed. Phosphorylated S6 protein expression was analyzed and representative images 
were selected from N=3 (MDA-MB-468) and N=2 (E0771) experiments. Data presented as the mean ± SEM. A 
one-way ANOVA with Dunnett’s multiple comparison test was used for data analysis of multiple groups. A P <0.05 
was considered statistically significant, with * indicating significance. Treatment of MDA-MB-468 and E0771 
TNBC cells with Everolimus or Everolimus and CQ in-combination resulted in decreased expression of the p-S6 
protein, downstream of mTOR (C, D). Western blotting representing expression levels of proteins of interest relative 
to housekeeping proteins 𝛂-tubulin. 
 
Furthermore, we hypothesized that treatment of BC cells with BMS-754807 would result 
in decreased expression of IGF-1R phosphorylation. IGF-1R is activated when bound to IGF-1 
which results in cell proliferation and metastasis23. We were unable to detect differences in IGF-
1R phosphorylation upon treatment of E0771 cells with BMS-754807 (Figure 7B). Although 
BMS-754807 is an IGF-1R inhibitor, it also inhibits insulin receptor (INSR), and BMS-754807 
may have disrupted INSR expression to a greater extent than IGF1R levels78.  
To determine whether autophagy was induced upon MRI treatment we analyzed p62 
expression. We hypothesized that treatment of E0771 cells with Everolimus or BMS-754807 
alone would lead to decreased expression levels of p62, a ubiquitin-binding protein that acts as a 
marker of autophagic flux79. When autophagy is induced, p62 is degraded and when autophagy is 
inhibited, p62 accumulates in the cell79. However, the results indicated that p62 levels were not 
affected by treatment with Everolimus or BMS-754807 alone and did not confirm autophagy was 
induced (Figure 7C). We also hypothesized that treatment of E0771 cells with Everolimus or 
BMS-754807 in combination with CQ would block autophagic flux leading to increased p62 
levels in the cell. However, the combination treatment of Everolimus or BMS-754807 with CQ 
did not confirm autophagy was inhibited (Figure 7C). However, phenotypic assays demonstrated 















Figure 7. Effects of Everolimus and BMS-754807 treatment on pIGF1R and p62 levels. 
E0771 cells were cultured in low-glucose media overnight and treated with 20 µM chloroquine (CQ), 1 µM BMS, 
15 or 30 nM Everolimus (MDA-MB-468, E0771 respectively), separately or in combination for 4 hours and lysed. 
Phosphorylated/total IGF1R (B) and p62 (C) protein expression was analyzed and representative images were 
selected from N=3 experiments. Data presented as the mean ± SEM. A one-way ANOVA with Dunnett’s multiple 
comparison test was used for data analysis of multiple groups. A P < 0.05 was considered statistically significant, 
with * indicating significance. Western blotting representing expression levels of proteins of interest relative to 
housekeeping proteins 𝛂-tubulin. 
 
V. Pharmacological agents mimicking CR and inhibiting autophagy work synergistically 
to hinder BC growth 
 
Everolimus or BMS-754807 in combination with CQ result in synergistic interactions 
 
To investigate whether combining metabolic reprogramming interventions with autophagy 
inhibition would synergistically inhibit growth of BC cell lines, viability of cells treated with 
MRI with and without CQ was measured via MTT assays. Synergistic potential was analyzed 
using the SynergyFinder software. SynergyFinder is an interactive web application used to 
analyze drug combination dose-response data. A synergistic effect is said to occur if the response 
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from two drugs added to a system is greater than the predicted response from the two drugs 
individually80. It can be determined as the excess of observed effect over expected effect as 
calculated by several synergy scoring models. The Bliss independence model was used for 
analysis which assumes that the fractional response of two drugs in combination equals the sum 
of the two fractional responses of each drug minus their product80. SynergyFinder is able to 
calculate a synergy score for the combination of two drugs over an average of all dose 
combination cells where a score less than -10 likely indicates an antagonistic interaction between 
two drugs, a score from -10 to 10 likely indicates an additive interaction between two drugs, and 
a score greater than 10 likely indicates a synergistic interaction between two drugs81.  
Unexpectedly, treatment of E0771 cells with Everolimus alone appeared to result in greater 
cytotoxic effects than the combination of Everolimus and CQ (Figure 8A). This result could be 
confounded due to limited growth inhibition of the Everolimus alone in this cell line. 
SynergyFinder produced a Bliss synergy score of -10.398 for the combination of Everolimus and 
CQ which is at the cutoff point for an additive or antagonistic interaction (Figure 8A). 
Interestingly in the MDA-MB-468s, the results indicated a synergistic interaction between 
Everolimus and CQ with a Bliss synergy score of 12.5 (Figure 8B). 
In the E0771s, the results indicated a synergistic interaction between BMS-754807 and CQ 
with a Bliss synergy score of 12.741 (Figure 8C). However, in the MDA-MB-468s, BMS and 









































Figure 8. Effects of combination treatments Everolimus or BMS-854807 + chloroquine on cell viability. 
Following 24 hours of nutrient restriction, E0771 (A) or MDA-MB-468 (B) cells are treated with Everolimus at 
increasing doses of 15.63 nM, 31.25 nM. 62.5 nM, 125 nM, 250 nM, 500 nM, and 1000 nM. E0771 (C) or MDA-
MB-468 (D) cells are treated with BMS-754807 at increasing doses of 0.313, 0.625, 1.25, 2.5, 5, 10, and 20 µM. 
Cells were treated for 24 hours before being treated with either 15 µM or 20 µM chloroquine for 24 hours. An MTT 
assay was conducted to measure % growth inhibition/cytotoxicity. Data presented as mean ± SD with axes x = 
log(concentration) and y = % growth inhibition/cytotoxicity for N=3 experiments. MTT data was analyzed using 
SynergyFinder to investigate the potential synergistic effect of CQ in combination with Everolimus or BMS-754807 
in E0771s (A,B) and MDA-MB-468s (C,D). Reference model used is Bliss independence model, utilizing % 
inhibition values from MTT data (N=3 experiments). Corresponding synergy scores for different drug combinations 





Obesity significantly increases an individual’s risk of developing and dying from breast 
cancer. This is a growing public health concern in the US as 41.9% of all women aged 20 and 
over are obese82. Dietary intervention research shows promise in attenuating obesity-related 
acceleration of cancer progression. For example, dietary modifications such as caloric restriction 
have been shown to reverse the adverse effects of DIO on BC growth and metastasis in murine 
models83. This project aimed to examine mechanisms underlying the anticancer effects of CR. 
Specifically, we tested the impact of CR regimens in reversing DIO-related transcriptional 
changes within the tumor microenvironment. Better understanding of the mechanisms 
contributing to CR’s beneficial effects on BC tumor progression is crucial to reducing poor 
health outcomes in obese populations. Further, despite promise for improving cancer outcomes 
in murine models, translating these approaches to humans has proven difficult due to concerns of 
low tolerance of extreme diets (feasibility) and safe use of these interventions in cancer 
patients28. Therefore, we utilized cell culture models to evaluate the effect of pharmacological 
agents, that mimic the beneficial effects of CR on IGF-1 and mTOR signaling, on triple-negative 
and basal-like breast cancer growth, and if the addition of autophagy inhibition would provide 
further benefit. Examining the ability of metabolic reprogramming interventions and autophagy 
inhibition to reduce BC progression allows for the potential to use more manageable treatments 
for BC patients than strenuous restriction regimens. 
As expected, DIO mice had significantly greater tumor mass compared to control. 
Moreover, formerly obese mice placed on a low-fat control diet did not exhibit a significant 
difference in tumor mass compared to the DIO mice, in agreement with previous findings from 
our laboratory84. Conversely, DIO mice on CR regimens showed significantly reduced tumor 
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mass compared to both DIO and control mice. These results are consistent with study findings 
demonstrating the ability of CR to reverse obesity-associated tumor progression85,86.  
This study provides evidence that DIO leads to the upregulation of genes and gene 
signatures supportive of tumor growth and progression. Compared to control mice, DIO mice 
displayed increased expression of TIMP-2 which has been shown to result in increased BC 
progression and shortened disease-free and overall survival53. Additionally, DIO mice showed 
decreased expression of tumor necrosis factor ligand, which encodes a protein involved in the 
induction of apoptosis in tumor cells, compared to control mice54. Furthermore, through GSEA 
analysis we found DIO, relative to control, enriched tumors for gene sets associated with tumor 
supportive processes including angiogenesis, a known hallmark of cancer for tumor 
development87. In contrast, obesity resulted in the underrepresentation of immune signaling 
pathways important for fighting cancer such as IFNα and IFNγ which serve as major antitumor 
immune mediators71. 
Interestingly, in agreement with significantly reduced tumor mass in CR mice compared 
to DIO, this study provides evidence that CR dietary interventions were able to reverse DIO-
related enrichment of protumorigenic gene sets including epithelial-to-mesenchymal transition 
(EMT) and hypoxia hallmark gene sets. Tumor hypoxia is associated with an increased risk of 
BC metastasis and mortality through the acquisition of the EMT phenotype, which is well 
established in the literature as a contributor to tumor progression, invasion, and metastasis89. 
Likewise, gene expression data provides evidence that CCR and ICR increased tumoral 
transcripts related to immune cell signaling. In CCR and ICR mice, transcripts related to Cd8 T 
cells and their activation/signaling pathways, which secrete cytotoxic mediators that suppress 
tumor growth, as well as multiple cytotoxic mediators (i.e. granzyme B and perforin)59,60,61. 
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Further, GSEA determined that DIO-related underrepresentation of immune signaling gene sets 
were reversed by both ICR and CCR interventions. Thus, these findings illustrate obesity’s role 
in reducing the activation of immune-related signaling pathways within the tumor 
microenvironment related to tumor suppression and the ability of CR to reverse these effects. 
This study focused on mTOR signaling due to mTOR’s critical role in tumor cell 
proliferation and metastasis and our hypothesis that mTOR signaling drives changes in the tumor 
microenvironment in obese vs. CR mice. Since mTOR signaling is downregulated by low 
nutrient availability and increased in the obese state, we hypothesized that mTOR signaling 
would be upregulated in DIO vs. all intervention groups. However, we found mTOR-related 
signaling, specifically the hallmark mTORC1 signaling and PI3K/AKT/mTOR signaling gene 
sets, were downregulated in DIO vs CCR. Leading edge analysis indicated that genes shown to 
be leading contributors to the enrichment of mTOR-related signaling in CCR mice were 
primarily involved in immune signaling. These finding may be attributed to the larger impact of 
CCR on increasing immune-regulated signaling on the tumor microenvironment rather than 
tumor cell induction of mTOR signaling for growth and survival advantages. Several studies 
have established how mTOR signaling is utilized by the immune system to regulate the 
expression of factors such as chemokines and cytokines involved in BC proliferation90,91. To 
validate the genes identified as leading contributors to the negative NES, RT-qPCR may be used 
in the future.  
Following the analysis of in vivo tumors from mice placed on CR regimens, this study 
tested whether metabolic reprogramming interventions which mimic CR and target IGF-1 (BMS-
754807) and mTOR (Everolimus) could induce similar anti-cancer effects in triple-negative and 
basal-like BC cells. It was found that treatment of MDA-MB-468 cells with Everolimus and 
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BMS-754807 resulted in significant growth inhibition at doses >15.63 nM and >0.625 uM 
respectively. Additionally, treatment of E0771s with BMS-754807 resulted in significant 
cytotoxic effects at doses >1.250 uM. Interestingly, treatment of E0771s with Everolimus did not 
differentially affect cell viability compared to vehicle. 
In both E0771s and MDA-MB-468s, this study confirmed the target inhibition of 
Everolimus on mTOR through decreased expression of pS6 which is located downstream of 
mTORC1. However, this study did not confirm the target inhibition of BMS-754807 on IGF-1 
signaling. Furthermore, this study did not confirm Everolimus and BMS-754807 induced 
autophagy and that CQ inhibited autophagy. One limitation is that when conducting Western 
immunoblotting, pIGF1R/total IGF1R and p62 expression were unable to be detected in the 
MDA-MB-468 cells. Furthermore, LC3BI/LC3BII ratio, a marker of autophagic flux, were 
unable to be detected in either cell line. Future work includes additional methodology for 
analyzing levels of autophagy (i.e. CytoID Detection Kit [Enzo Life Sciences]). 
Furthermore, we aimed to determine the anti-cancer effects of combining MRIs with 
autophagy inhibition. Although we were not able to examine the effects of the MRIs on 
autophagy induction, we did find a synergistic interaction between MRIs and autophagy inhibitor 
CQ. Specifically, BMS + CQ synergistically inhibited E0771 viability and Everolimus + CQ 
synergistically inhibited MDA-MB-468 viability. These findings agree with a study conducted 
by Grimaldi et. al, who demonstrated that the combination of Everolimus and CQ was 
synergistic in inducing growth inhibition92. Our results indicate the potential for metabolic 




 This work contributes to our understanding on the impact of dietary energy balance on 
the tumor microenvironment and progression of basal-like breast cancer.  In addition, it tests the 
efficacy of pharmacological interventions mimicking calorie restriction and autophagy inhibition 
as treatments for triple negative and basal-like breast cancer. The knowledge gained from this 
research could inform efforts directed towards the development of therapeutic options to reduce 
progression of aggressive, basal-like and triple-negative breast cancer subtypes which currently 




















 In summary, the results from this study show that obesity induces gene expression 
alterations within the tumor microenvironment that support tumor growth, including increased 
angiogenesis and reduced immune signaling. Our results demonstrate that dietary interventions, 
CCR and ICR, effectively reverse the protumorigenic effects of obesity, reducing angiogenic 
signaling and increasing the activation and abundance of immune cell markers within the tumor 
microenvironment. Further, when examining the ability of pharmacological MRIs mimicking CR 
and autophagy inhibition as treatments for triple-negative and basal-like breast cancer, our 
findings show the potential for these combination treatments to work synergistically against 
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Appendix A: TAC Analysis Differential Gene Expression Data 
Table 3. Significantly altered genes in DIO vs. Control groups using TAC analysis  
 
Table 4. Significantly altered genes in DIO vs. CCR groups using TAC analysis  
Description Gene Symbol Fold Change P-val FDR P-val
plasminogen activator, tissue Plat 2.58 7.38E-06 5.00E-03
troponin T2, cardiac Tnnt2 2.57 7.00E-04 4.03E-02
gene regulated by estrogen in breast cancer protein Greb1 2.21 7.14E-06 5.00E-03
solute carrier family 14 (urea transporter), member 1 Slc14a1 2.1 5.97E-05 1.17E-02
gene regulated by estrogen in breast cancer protein Greb1 2.06 1.00E-04 1.55E-02
solute carrier family 14 (urea transporter), member 1 Slc14a1 1.86 5.00E-04 3.21E-02
Fc receptor-like S, scavenger receptor Fcrls 1.85 1.00E-04 1.55E-02
protocadherin beta 21 Pcdhb21 1.75 2.36E-05 7.70E-03
solute carrier organic anion transporter family, member 1a5 Slco1a5 1.75 4.24E-05 1.01E-02
GLI-Kruppel family member GLI2 Gli2 1.74 2.84E-05 8.30E-03
DNA segment, Chr 15, ERATO Doi 30, expressed D15Ertd30e 1.73 6.00E-04 3.49E-02
T-box 3 Tbx3 1.72 5.20E-05 1.13E-02
leucine-rich repeat LGI family, member 2 Lgi2 1.7 1.10E-03 4.94E-02
splA/ryanodine receptor domain and SOCS box containing 1 Spsb1 1.68 1.00E-04 1.47E-02
attractin like 1 Atrnl1 1.67 1.99E-05 7.50E-03
dispatched homolog 2 (Drosophila) Disp2 1.67 2.27E-05 7.70E-03
1.67 2.00E-04 2.23E-02
procollagen C-endopeptidase enhancer 2 Pcolce2 1.65 4.81E-06 4.00E-03
glycerophosphodiester phosphodiesterase domain containing 5 Gdpd5 1.65 2.97E-06 3.30E-03
cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) Chrna1 1.64 2.00E-04 2.12E-02
serine (or cysteine) peptidase inhibitor, clade F, member 1 Serpinf1 1.63 1.11E-05 5.80E-03
placenta expressed transcript 1 Plet1 1.62 2.00E-04 1.94E-02
beta galactoside alpha 2,6 sialyltransferase 1 St6gal1 1.62 2.00E-04 1.96E-02
latent transforming growth factor beta binding protein 3 Ltbp3 1.61 4.37E-06 3.80E-03
TSC22 domain family, member 1 Tsc22d1 1.61 8.62E-07 1.70E-03
PDZ and LIM domain 4 Pdlim4 1.58 2.00E-04 1.98E-02
Description Gene Symbol Fold Change P-val FDR P-val
guanylate binding protein 7 Gbp7 -1.58 3.11E-06 2.33E-02
meiosis specific with OB domains Meiob -1.8 5.89E-07 1.33E-02
Rho family GTPase 3 Rnd3 1.51 2.31E-05 4.89E-02
tissue inhibitor of metalloproteinase 2 Timp2 1.55 1.71E-05 4.89E-02




serine (or cysteine) peptidase inhibitor, clade F, member 1 Serpinf1 1.58 4.00E-05 9.80E-03
1.57 8.17E-05 1.35E-02
heat shock protein 4 Hspa4 1.57 4.00E-04 2.87E-02
solute carrier family 18, subfamily B, member 1 Slc18b1 1.56 2.00E-04 2.14E-02
TSC22 domain family, member 1 Tsc22d1 1.55 1.12E-06 2.00E-03
serine/arginine-rich splicing factor 7 Srsf7 1.54 1.72E-05 7.10E-03
peroxisomal biogenesis factor 6 Pex6 1.54 1.98E-05 7.50E-03
peroxisomal biogenesis factor 6 Pex6 1.54 2.52E-06 3.20E-03
pyrroline-5-carboxylate reductase 1 Pycr1 1.54 5.17E-07 1.50E-03
collagen, type XVIII, alpha 1 Col18a1 1.53 8.72E-07 1.70E-03
SH3 domain protein D19 Sh3d19 1.53 3.05E-05 8.50E-03
jagged 1 Jag1 1.53 2.88E-07 1.20E-03
integrin beta 5 Itgb5 1.52 5.80E-05 1.16E-02
platelet derived growth factor receptor, beta polypeptide Pdgfrb 1.52 7.00E-04 4.08E-02
leucine rich repeat protein 3, neuronal Lrrn3 1.51 4.00E-04 3.14E-02
GLI-Kruppel family member GLI2 Gli2 1.51 7.74E-05 1.33E-02
TGF-beta1-induced anti-apoptotic factor 2 Tiaf2 1.51 2.00E-04 2.04E-02
reticulocalbin 3, EF-hand calcium binding domain Rcn3 1.5 4.00E-04 3.07E-02
cell cycle progression 1 Ccpg1 1.5 9.20E-06 5.40E-03
uncharacterized LOC328066 LOC328066 -1.51 9.33E-05 1.42E-02
Fas ligand (TNF superfamily, member 6) Fasl -1.51 4.00E-04 3.01E-02
-1.51 7.00E-04 4.15E-02
transmembrane protein 71 Tmem71 -1.51 2.00E-04 2.31E-02
ribosomal protein S20 Rps20 -1.52 8.35E-05 1.36E-02
CDGSH iron sulfur domain 2 Cisd2 -1.52 6.82E-09 2.00E-04
paired-Ig-like receptor A2; paired-Ig-like receptor A6 Pira2; Pira6 -1.53 1.59E-05 6.90E-03
killer cell lectin-like receptor subfamily C, member 1 Klrc1 -1.53 8.00E-04 4.16E-02
small integral membrane protein 4 Smim4 -1.54 3.00E-04 2.59E-02
histone cluster 1, H1c Hist1h1c -1.54 2.00E-04 2.10E-02
T cell receptor gamma, constant 1; T-cell receptor gamma, constant 2 Tcrg-C1; Tcrg-C2 -1.54 9.00E-04 4.46E-02
mindbomb homolog 1 (Drosophila) Mib1 -1.54 3.00E-04 2.43E-02
phosphatidylinositol-specific phospholipase C, X domain containing 2 Plcxd2 -1.54 8.95E-05 1.40E-02
-1.55 6.00E-04 3.75E-02
chemokine (C-X-C motif) ligand 16 Cxcl16 -1.55 4.00E-04 3.06E-02
transferrin receptor Tfrc -1.55 6.14E-06 4.70E-03
ectonucleoside triphosphate diphosphohydrolase 1 Entpd1 -1.56 5.00E-04 3.21E-02
solute carrier family 15, member 3 Slc15a3 -1.56 6.00E-04 3.80E-02
cilia and flagella associated protein 69 Cfap69 -1.56 2.00E-04 1.86E-02
killer cell lectin-like receptor subfamily B member 1B Klrb1b -1.56 2.00E-04 1.83E-02
muscleblind-like 3 (Drosophila) Mbnl3 -1.57 7.47E-06 5.00E-03




hydroxyacylglutathione hydrolase-like Haghl -1.58 3.80E-05 9.60E-03
hydroxyacylglutathione hydrolase-like Haghl -1.58 3.00E-05 8.50E-03
coronin, actin binding protein 2A Coro2a -1.58 9.00E-04 4.62E-02
predicted gene, 37416; predicted gene, 39743; predicted gene, 40611; predicted gene, 40814; predicted gene, 41035; predicted gene, 41476; uncharacterized LOC105244034Gm37416; Gm39743; Gm40611; Gm40814; Gm41035; Gm41476; LOC105244034-1.6 3.00E-04 2.40E-02
C-type lectin domain family 4, member e Clec4e -1.61 1.22E-05 6.10E-03
CD300 antigen like family member F Cd300lf -1.61 6.87E-05 1.25E-02
-1.61 5.00E-04 3.27E-02
phosphotyrosine interaction domain containing 1 Pid1 -1.62 1.77E-05 7.10E-03
C-type lectin domain family 5, member a Clec5a -1.62 6.00E-04 3.61E-02
cathepsin W Ctsw -1.63 6.17E-05 1.17E-02
-1.64 9.00E-04 4.52E-02
histone cluster 1, H1c Hist1h1c -1.64 5.96E-05 1.17E-02
transmembrane 4 superfamily member 1 Tm4sf1 -1.64 6.00E-04 3.80E-02
leukocyte immunoglobulin-like receptor, subfamily B, member 4B; leukocyte immunoglobulin-like receptor, subfamily B, member 4ALilr4b; Lilrb4a -1.6 3.00E-05 8.50E-03
interleukin 18 binding protein Il18bp -1.65 1.00E-03 4.76E-02
guanine nucleotide binding protein, alpha 13 Gna13 -1.67 5.91E-06 4.60E-03
G protein-coupled receptor 35 Gpr35 -1.68 1.00E-03 4.80E-02
sphingomyelin phosphodiesterase 4 Smpd4 -1.69 2.47E-07 1.20E-03
killer cell lectin-like receptor, subfamily A, member 7; killer cell lectin-like receptor 7Klra ; LOC100862438 -1.7 8.47E-05 1.37E-02
sphingomyelin phosphodiesterase 4 Smpd4 -1.7 7.52E-07 1.70E-03
transferrin receptor Tfrc -1.71 1.17E-05 6.00E-03
chemokine (C-C motif) receptor 1 Ccr1 -1.71 7.00E-04 3.93E-02
-1.75 5.56E-05 1.15E-02
coagulation factor X F10 -1.77 2.00E-04 2.28E-02
interleukin 1 receptor antagonist Il1rn -1.78 1.08E-05 5.80E-03
interleukin 1 receptor antagonist Il1rn -1.78 7.04E-06 5.00E-03
signal-regulatory protein beta 1-like; signal-regulatory protein beta 1A; signal-regulatory protein beta 1BLOC100038947; Sirpb1a; Sirpb1b-1.79 6.00E-04 3.56E-02
guanylate binding protein 2 Gbp2 -1.81 7.16E-05 1.28E-02
C-type lectin domain family 4, member e Clec4e -1.83 1.00E-03 4.75E-02
immunoresponsive gene 1 Irg1 -1.83 1.00E-04 1.74E-02
adrenergic receptor kinase, beta 2 Adrbk2 -1.84 9.00E-04 4.43E-02
leukocyte-associated Ig-like receptor 1 Lair1 -1.84 4.00E-04 3.09E-02
transmembrane 4 superfamily member 1 Tm4sf1 -1.85 9.44E-05 1.42E-02
fatty acid binding protein 5, epidermal Fabp5 -1.85 3.00E-04 2.47E-02
elongation protein 4 homolog (S. cerevisiae) Elp4 -1.86 1.72E-05 7.10E-03
C-type lectin domain family 4, member a2 Clec4a2 -1.86 8.87E-05 1.40E-02
B cell leukemia/lymphoma 2 related protein A1a; B cell leukemia/lymphoma 2 related protein A1b; B cell leukemia/lymphoma 2 related protein A1dBcl2a1a; Bcl2a1b; Bcl2a1d-1.86 1.00E-03 4.65E-02
cystatin F (leukocystatin) Cst7 -1.88 6.00E-04 3.59E-02
ankyrin repeat and BTB (POZ) domain containing 2 Abtb2 -1.88 4.00E-04 2.99E-02
mast cell immunoglobulin like receptor 1 Milr1 -1.89 2.00E-04 2.23E-02
guanylate binding protein 2 Gbp2 -1.89 5.08E-05 1.13E-02
hydroxyacylglutathione hydrolase-like Haghl -1.9138537 3.50E-04 2.45E-02




allograft inflammatory factor 1-like Aif1l -1.94 3.61E-05 9.30E-03
CD200 receptor 4 Cd200r4 -1.98 4.00E-04 2.94E-02
interleukin 2 receptor, beta chain Il2rb -1.98 8.46E-06 5.30E-03
leukocyte-associated Ig-like receptor 1 Lair1 -1.99 4.00E-04 3.01E-02
SLAM family member 7 Slamf7 -2.02 8.43E-06 5.30E-03
phospholipase B domain containing 1 Plbd1 -2.06 6.00E-04 3.80E-02
TRAF-interacting protein with forkhead-associated domain, family member B Tifab -2.08 3.00E-04 2.67E-02
secreted and transmembrane 1A Sectm1a -2.14 8.00E-04 4.31E-02
predicted pseudogene 10693; predicted gene 14548; leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 6; paired-Ig-like receptor A1; paired-Ig-like receptor A11; paired-Ig-like receptor A2; paired-Ig-like receptor A4; paired-Ig-like receptor A5; paired-Ig-like receptor A6; paired-Ig-like receptor A7; paired Ig-like receptor BGm10693; Gm14548; Lilra6; Pira1  Pira11; Pira2; Pira4; Pira5; Pira6; Pira7; Pi b-2.14 2.00E-04 2.22E-02
killer cell lectin-like receptor subfamily B member 1B Klrb1b -2.15 1.59E-05 6.90E-03
predicted gene 6377 Gm6377 -2.18 1.00E-04 1.67E-02
SLAM family member 8 Slamf8 -2.19 7.89E-05 1.33E-02
interferon induced transmembrane protein 1 Ifitm1 -2.21 6.00E-04 3.69E-02
formyl peptide receptor 2 Fpr2 -2.22 9.00E-04 4.41E-02
interleukin 7 receptor Il7r -2.24 3.15E-06 3.30E-03
family with sequence similarity 26, member F Fam26f -2.24 9.00E-04 4.58E-02
interleukin 7 receptor Il7r -2.25 2.59E-05 7.90E-03
expressed sequence AW112010 AW112010 -2.29 8.00E-04 4.30E-02
CD8 antigen, alpha chain Cd8a -2.3 1.00E-03 4.80E-02
chemokine (C-X-C motif) ligand 9 Cxcl9 -2.32 9.00E-04 4.46E-02
paired-Ig-like receptor A1; paired-Ig-like receptor A2; paired-Ig-like receptor A6Pira1; Pira2; Pira6 -2.35 8.25E-07 1.70E-03
immunoglobulin superfamily, member 6 Igsf6 -2.36 2.00E-04 1.83E-02
natural killer cell group 7 sequence Nkg7 -2.38 3.10E-05 8.60E-03
hepatitis A virus cellular receptor 2 Havcr2 -2.39 2.63E-06 3.20E-03
killer cell lectin-like receptor, subfamily A, member 3; killer cell lectin-like receptor subfamily A, member 9Klra3; Klra -2.42 1.00E-04 1.73E-02
chemokine (C-C motif) receptor 1 Ccr1 -2.42 7.00E-04 3.93E-02
killer cell lectin-like receptor subfamily K, member 1 Klrk1 -2.55 9.70E-06 5.60E-03
killer cell lectin-like receptor subfamily B member 1B Klrb1b -2.57 6.76E-05 1.25E-02
guanylate-binding protein 8 Gbp8 -2.57 1.00E-04 1.55E-02
C-type lectin domain family 7, member a Clec7a -2.66 6.06E-05 1.17E-02
killer cell lectin-like receptor subfamily B member 1B Klrb1b -2.87 4.25E-05 1.01E-02
predicted gene, 42362 Gm42362 -3.07 1.00E-03 4.70E-02
killer cell lectin-like receptor subfamily B member 1B Klrb1b -3.12 1.29E-05 6.10E-03
perforin 1 (pore forming protein) Prf1 -3.16 8.43E-07 1.70E-03
killer cell lectin-like receptor, subfamily D, member 1 Klrd1 -3.29 1.00E-04 1.50E-02
granzyme B Gzmb -3.44 1.98E-07 1.20E-03
killer cell lectin-like receptor subfamily C, member 1 Klrc1 -3.44 9.12E-06 5.40E-03
granzyme E Gzme -4.18 5.00E-04 3.31E-02
granzyme D; granzyme E Gzmd; Gzme -6.35 3.00E-04 2.67E-02
granzyme F Gzmf -7 6.82E-05 1.25E-02
granzyme D Gzmd -7.14 8.00E-04 4.31E-02
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Table 5. Significantly altered genes in DIO vs. ICR groups using TAC Analysis 
 
 
Description Gene Symbol Fold Change P-val FDR P-val
growth associated protein 43 Gap43 4.04 0.0051 0.0432
insulin-like growth factor binding protein 3 Igfbp3 3.51 0.0004 0.0092
interleukin 33 Il33 3.34 6.09E-05 0.0031
matrix metallopeptidase 3 Mmp3 3.22 0.0061 0.0479
solute carrier family 14 (urea transporter), member 1 Slc14a1 3.05 1.37E-06 0.0004
troponin T2, cardiac Tnnt2 3.01 0.0005 0.0105
plasminogen activator, tissue Plat 2.81 6.42E-07 0.0003
troponin T2, cardiac Tnnt2 2.77 0.0003 0.0088
crystallin, alpha B Cryab 2.75 0.0064 0.0496
3-oxoacid CoA transferase 1 Oxct1 2.68 3.38E-07 0.0002
metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) Malat1 2.66 0.0002 0.0054
breast carcinoma amplified sequence 2 Bcas2 2.66 4.63E-06 0.0007
pitrilysin metallepetidase 1 Pitrm1 2.6 3.59E-06 0.0006
gene regulated by estrogen in breast cancer protein Greb1 2.54 6.45E-05 0.0032
insulin-like growth factor binding protein 3 Igfbp3 2.51 0.003 0.0311
heat shock protein 1B Hspa1b 2.5 0.0003 0.0078
praja ring finger 1, E3 ubiquitin protein ligase Pja1 2.5 1.17E-07 0.0001
sine oculis-related homeobox 4 Six4 2.5 2.31E-06 0.0005
heat shock protein 1B Hspa1b 2.5 0.0003 0.0075
Ral GTPase activating protein, alpha subunit 1 Ralgapa1 2.4 0.0003 0.0088
solute carrier family 14 (urea transporter), member 1 Slc14a1 2.4 0.0001 0.0043
5' nucleotidase, ecto Nt5e 2.39 0.0009 0.0155
actin filament associated protein 1 Afap1 2.39 3.14E-05 0.0021
endothelial cell-specific molecule 1 Esm1 2.38 0.0008 0.0139
GTP binding protein 4 Gtpbp4 2.34 4.71E-06 0.0007
cysteine-rich hydrophobic domain 1 Chic1 2.33 1.83E-05 0.0015
eukaryotic translation initiation factor 2A Eif2a 2.29 0.0002 0.0064
heat shock protein 1B Hspa1b 2.25 0.0004 0.0101
2.23 5.16E-07 0.0003
endothelin receptor type A Ednra 2.2 0.0009 0.0148
transmembrane 9 superfamily member 2 Tm9sf2 2.2 5.04E-07 0.0003
acid phosphatase, prostate Acpp 2.18 0.0003 0.0085
sine oculis-related homeobox 4 Six4 2.17 1.76E-06 0.0005
neuronal pentraxin 1 Nptx1 2.16 1.15E-06 0.0004
kelch-like 24 Klhl24 2.15 1.67E-07 0.0001
multiple inositol polyphosphate histidine phosphatase 1 Minpp1 2.13 3.70E-06 0.0006
netrin 1 Ntn1 2.12 0.0026 0.0286
interferon activated gene 204 Ifi204 2.12 0.001 0.0165
40S ribosomal protein S21 pseudogene; ribosomal protein S21 LOC102638850; Rps21 2.09 3.52E-06 0.0006
metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) Malat1 2.08 1.19E-09 2.59E-05
olfactomedin 1 Olfm1 2.08 7.02E-05 0.0034
heat shock protein 8 Hspa8 2.08 2.36E-06 0.0005
heat shock protein 1A Hspa1a 2.07 0.0011 0.0173
rearranged L-myc fusion sequence Rlf 2.05 3.67E-06 0.0006
RB1-inducible coiled-coil 1 Rb1cc1 2.05 4.27E-07 0.0002
gene regulated by estrogen in breast cancer protein Greb1 2.05 0.0006 0.0123
acid phosphatase 1, soluble; low molecular weight phosphotyrosine protein phosphatase Acp1; LOC102642088 2.05 1.98E-05 0.0016
solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 5 Slc25a5 2.04 0.0001 0.0048
tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 2 Tnks2 2.03 0.004 0.0376
Rho GTPase activating protein 6 Arhgap6 2.03 0.0001 0.0044
SH3 domain protein D19 Sh3d19 2.02 5.19E-05 0.0028
clusterin Clu 2.02 0.0004 0.0097
senataxin Setx 2.02 5.22E-06 0.0007
TAF15 RNA polymerase II, TATA box binding protein (TBP)-associated factor Taf15 2.02 0.0012 0.0181
glutamine and serine rich 1 Qser1 2.02 0.0006 0.012
neuronal pentraxin 1 Nptx1 2.01 5.73E-06 0.0008
expressed sequence AI314180 AI314180 1.99 0.0017 0.0219
phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoribosylaminoimidazole, succinocarboxamide synthetasePaics 1.99 5.45E-06 0.0007
protein O-fucosyltransferase 2 Pofut2 1.98 1.83E-08 5.13E-05
zinc finger protein 318 Zfp318 1.98 8.52E-05 0.0038
Ras-related GTP binding D Rragd 1.97 5.04E-05 0.0028
RAD21 homolog (S. pombe) Rad21 1.97 9.72E-06 0.0011
expressed sequence AI314180 AI314180 1.96 6.87E-05 0.0033
melanoma inhibitory activity 3 Mia3 1.95 4.61E-06 0.0007
predicted gene, 21451; lysyl oxidase-like 2 Gm21451; Loxl2 1.95 0.0005 0.0102
tubby like protein 4 Tulp4 1.94 4.13E-08 7.04E-05
nuclear receptor subfamily 3, group C, member 1 Nr3c1 1.93 6.05E-06 0.0008
SH3 domain protein D19 Sh3d19 1.92 1.88E-05 0.0015
glutaredoxin 3 Glrx3 1.92 2.31E-06 0.0005
chloride channel CLIC-like 1 Clcc1 1.91 1.56E-06 0.0004
proline-rich coiled-coil 2C Prrc2c 1.91 4.20E-06 0.0007
1.91 0.0021 0.025
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2 Pcmtd2 1.91 4.18E-06 0.0007
peroxiredoxin 4 Prdx4 1.91 1.24E-05 0.0012
topoisomerase (DNA) II beta Top2b 1.91 0.002 0.0245
protein phosphatase 1, catalytic subunit, beta isoform Ppp1cb 1.9 7.28E-06 0.0009
ubiquitin-associated protein 2-like Ubap2l 1.9 7.45E-06 0.0009
zinc finger protein 292 Zfp292 1.87 6.76E-06 0.0009
1.87 3.94E-06 0.0007
T-box 3 Tbx3 1.87 6.60E-06 0.0008
platelet derived growth factor receptor, beta polypeptide Pdgfrb 1.87 5.35E-05 0.0029
predicted gene, 21596; high mobility group box 1 Gm21596; Hmgb1 1.87 4.18E-06 0.0007
signal recognition particle 54A; signal recognition particle 54B; signal recognition particle 54CSrp54a; Srp54b; Srp54c 1.87 0.0005 0.0103
leucine-rich repeat LGI family, member 2 Lgi2 1.87 0.0003 0.0074
akirin 1 Akirin1 1.87 5.81E-06 0.0008
growth arrest and DNA-damage-inducible 45 alpha Gadd45a 1.85 0.0029 0.0305
zinc finger protein 62 Zfp62 1.85 6.86E-07 0.0003
purine rich element binding protein A Pura 1.85 1.95E-05 0.0016
RAS-like, family 10, member A Rasl10a 1.84 0.0025 0.0278
cadherin 13 Cdh13 1.84 7.19E-06 0.0009
DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 Ddx17 1.84 0.0004 0.0096
dedicator of cytokinesis 10 Dock10 1.83 0.0003 0.0083
1.83 0.0024 0.0269
regulator of G-protein signaling 19 Rgs19 1.83 1.83E-05 0.0015
SH3 domain protein D19 Sh3d19 1.82 6.72E-06 0.0009
paired related homeobox 1 Prrx1 1.82 2.55E-08 5.13E-05
RIKEN cDNA 1810011O10 gene 1810011O10Rik 1.82 6.46E-05 0.0032
1.82 2.77E-06 0.0006
tyrosyl-tRNA synthetase 2 (mitochondrial) Yars2 1.81 0.0001 0.0049
interferon activated gene 204; interferon activated gene 205; myeloid cell nuclear differentiation antigen; myeloid nuclear differentiation antigen likeIfi204; I i205; Mnda; Mndal 1.81 0.0026 0.0285
ataxin 2 Atxn2 1.81 9.25E-08 0.0001
neuronal guanine nucleotide exchange factor Ngef 1.8 0.0005 0.0109
atypical chemokine receptor 3 Ackr3 1.8 2.37E-06 0.0005
cystatin E/M Cst6 1.8 4.29E-07 0.0002
ubiquitin-like, containing PHD and RING finger domains 2 Uhrf2 1.79 1.36E-08 5.13E-05
utrophin Utrn 1.79 0.0014 0.0201
heat shock protein 4 Hspa4 1.78 4.89E-05 0.0027
1.78 0.0007 0.0127
a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 4 Adamts4 1.78 0.0002 0.006
laminin B1 Lamb1 1.77 2.04E-05 0.0016
transmembrane emp24-like trafficking protein 10 (yeast) Tmed10 1.77 9.89E-07 0.0004
methylenetetrahydrofolate dehydrogenase (NADP+ dependent), methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthaseMthfd1 1.77 2.14E-06 0.0005
activating signal cointegrator 1 complex subunit 3 Ascc3 1.77 1.43E-05 0.0013
5' nucleotidase, ecto Nt5e 1.77 0.0009 0.0152
transmembrane emp24 protein transport domain containing 5 Tmed5 1.76 6.66E-05 0.0033
R3H domain containing 1 R3hdm1 1.76 1.56E-05 0.0014
OCIA domain containing 2 Ociad2 1.76 0.0028 0.0302
calcineurin-like EF hand protein 1 Chp1 1.76 6.59E-08 9.90E-05
amphiregulin Areg 1.76 0.0009 0.0147
carboxypeptidase E Cpe 1.76 9.46E-06 0.0011
zinc finger, DHHC domain containing 20 Zdhhc20 1.76 0.0002 0.007
RIKEN cDNA 1810011O10 gene 1810011O10Rik 1.75 3.67E-05 0.0023
leucine-rich repeat LGI family, member 2 Lgi2 1.75 6.11E-07 0.0003
interleukin 1 receptor accessory protein Il1rap 1.75 0.0001 0.005




junction-mediating and regulatory protein Jmy 1.73 0.0032 0.0327
high density lipoprotein (HDL) binding protein Hdlbp 1.73 0.0003 0.0085
cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) Chrna1 1.73 4.02E-05 0.0024
family with sequence similarity 171, member A2 Fam171a2 1.72 0.0006 0.0122
DNA segment, Chr 15, ERATO Doi 30, expressed D15Ertd30e 1.72 0.0008 0.0136
40S ribosomal protein S6; ribosomal protein S6 LOC105244208; Rps6 1.72 0.0001 0.0049
karyopherin (importin) beta 1 Kpnb1 1.72 1.06E-06 0.0004
acid phosphatase, prostate Acpp 1.72 0.0014 0.0194
hydroxysteroid (17-beta) dehydrogenase 4 Hsd17b4 1.72 1.13E-06 0.0004
Rho GTPase activating protein 29 Arhgap29 1.71 4.87E-07 0.0003
Smg-6 homolog, nonsense mediated mRNA decay factor (C. elegans) Smg6 1.71 5.52E-06 0.0008
RUN and FYVE domain-containing 2 Rufy2 1.71 0.0002 0.0063
DnaJ (Hsp40) homolog, subfamily A, member 1 Dnaja1 1.71 4.97E-05 0.0027
dispatched homolog 2 (Drosophila) Disp2 1.71 4.85E-06 0.0007
zinc finger E-box binding homeobox 2 Zeb2 1.71 0.0001 0.0048
tubulin, beta 2B class IIB Tubb2b 1.71 0.0061 0.0479
serine (or cysteine) peptidase inhibitor, clade F, member 1 Serpinf1 1.71 2.37E-06 0.0005
RAB GTPase activating protein 1 Rabgap1 1.7 0.0021 0.0249
high mobility group box 2 Hmgb2 1.7 0.0005 0.0109
ets variant 1 Etv1 1.7 0.0026 0.0286
canopy 2 homolog (zebrafish) Cnpy2 1.7 4.60E-06 0.0007
predicted pseudogene 4024; transmembrane emp24-like trafficking protein 10 (yeast) Gm4024; Tmed10 1.69 1.12E-05 0.0012
retinoblastoma binding protein 9 Rbbp9 1.69 5.57E-06 0.0008
Rho GTPase activating protein 5 Arhgap5 1.69 0.001 0.0162
kelch-like 24 Klhl24 1.68 0.0004 0.0096
SPEG complex locus Speg 1.68 0.0002 0.0057
cytochrome c oxidase assembly protein 15 Cox15 1.67 3.02E-05 0.002
protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I); WD repeat domain 92Ppp3r1; Wdr92 1.67 1.21E-05 0.0012
small EDRK-rich factor 1 Serf1 1.67 0.0003 0.0074
T-box 3 Tbx3 1.67 3.30E-05 0.0021
activating transcription factor 4 Atf4 1.67 2.53E-06 0.0005
expressed sequence C80889 C80889 1.67 0.0015 0.0207
peroxiredoxin 1 Prdx1 1.67 3.84E-06 0.0006
leucine-zipper-like transcriptional regulator, 1 Lztr1 1.67 4.49E-08 7.23E-05
chromodomain helicase DNA binding protein 8 Chd8 1.66 0.0004 0.0099
GCN1 general control of amino-acid synthesis 1-like 1 (yeast) Gcn1l1 1.66 0.0027 0.0296
TSC22 domain family, member 1 Tsc22d1 1.66 2.08E-06 0.0005
zinc finger protein 317 Zfp317 1.66 0.0006 0.0118
cyclin I Ccni 1.66 4.54E-06 0.0007
1.66 8.30E-07 0.0003
Rho guanine nucleotide exchange factor (GEF) 3 Arhgef3 1.66 0.001 0.0162
influenza virus NS1A binding protein Ivns1abp 1.65 2.32E-08 5.13E-05
CD47 antigen (Rh-related antigen, integrin-associated signal transducer) Cd47 1.65 7.37E-07 0.0003
ADP-ribosylation factor guanine nucleotide-exchange factor 1(brefeldin A-inhibited) Arfgef1 1.65 1.46E-05 0.0013
clusterin Clu 1.65 0.0027 0.0298
high density lipoprotein (HDL) binding protein Hdlbp 1.65 0.0002 0.0059
zinc finger protein 462 Zfp462 1.65 0.0004 0.0094
importin 4 Ipo4 1.65 1.02E-06 0.0004
1.65 2.00E-05 0.0016
proline-rich nuclear receptor coactivator 2 Pnrc2 1.64 0.0031 0.0318
myosin X Myo10 1.64 0.0046 0.0403
myelin protein zero-like 1 Mpzl1 1.64 4.23E-05 0.0025
serine (or cysteine) peptidase inhibitor, clade H, member 1 Serpinh1 1.64 7.56E-06 0.0009
extracellular matrix protein 1 Ecm1 1.64 3.23E-06 0.0006
zinc finger protein 36, C3H type-like 1 Zfp36l1 1.64 1.04E-07 0.0001
calmodulin regulated spectrin-associated protein family, member 2 Camsap2 1.64 0.0008 0.0143
nischarin Nisch 1.64 3.13E-07 0.0002
kinesin family member 5B Kif5b 1.64 3.35E-05 0.0022
SECIS binding protein 2-like Secisbp2l 1.64 3.38E-09 2.59E-05
ninein-like Ninl 1.64 5.27E-05 0.0028
chondroitin sulfate N-acetylgalactosaminyltransferase 1 Csgalnact1 1.64 0.0064 0.0497
TSC22 domain family, member 1 Tsc22d1 1.63 4.90E-07 0.0003
SH2 domain containing 5 Sh2d5 1.63 0.0034 0.0337
plectin Plec 1.63 9.83E-05 0.0041
centrosomal protein 68 Cep68 1.63 0.0021 0.0253
serine/arginine-rich splicing factor 11 Srsf11 1.63 1.00E-05 0.0011
myosin, light polypeptide kinase Mylk 1.63 0.0048 0.0416
protein phosphatase 1A, magnesium dependent, alpha isoform Ppm1a 1.63 4.40E-06 0.0007
pericentriolar material 1 Pcm1 1.63 4.53E-05 0.0026
Rap1 interacting factor 1 homolog (yeast) Rif1 1.63 0.0003 0.0085
annexin A1 Anxa1 1.63 0.0026 0.0287
Rho GTPase activating protein 6 Arhgap6 1.63 0.0009 0.0147
PHD finger protein 3 Phf3 1.62 0.0004 0.0095
Rho GTPase activating protein 6 Arhgap6 1.62 0.0017 0.0219
nuclear casein kinase and cyclin-dependent kinase substrate 1 Nucks1 1.62 3.60E-07 0.0002
transformer 2 alpha homolog (Drosophila) Tra2a 1.62 9.05E-07 0.0003
zinc finger protein X-linked Zfx 1.62 0.0004 0.0101
integrin alpha 6 Itga6 1.62 2.24E-07 0.0002
reticulocalbin 3, EF-hand calcium binding domain Rcn3 1.62 0.0004 0.0094
lysine (K)-specific demethylase 5A Kdm5a 1.62 1.44E-05 0.0013
sprouty protein with EVH-1 domain 1, related sequence Spred1 1.61 0.0001 0.0042
2-phosphoxylose phosphatase 1 Pxylp1 1.61 3.92E-06 0.0007
RNA binding motif protein 25 Rbm25 1.61 0.0009 0.0148
protein phosphatase 1, catalytic subunit, beta isoform Ppp1cb 1.61 1.04E-05 0.0011
1.61 0.0005 0.0109
NIMA (never in mitosis gene a)-related expressed kinase 1 Nek1 1.61 0.0043 0.039
inhibitor of Bruton agammaglobulinemia tyrosine kinase Ibtk 1.61 0.0006 0.0122
RNA binding motif protein 26 Rbm26 1.61 5.28E-07 0.0003
acylphosphatase 1, erythrocyte (common) type Acyp1 1.61 0.0038 0.036
kinesin family member 2A Kif2a 1.61 0.001 0.0158
platelet derived growth factor receptor, alpha polypeptide Pdgfra 1.61 0.0035 0.0341
protocadherin beta 21 Pcdhb21 1.61 0.0004 0.0093
sprouty homolog 2 (Drosophila) Spry2 1.61 1.59E-05 0.0014
heat shock protein 12B Hspa12b 1.6 9.71E-05 0.0041
laminin B1 Lamb1 1.6 1.09E-05 0.0011
Ras-related GTP binding D Rragd 1.6 0.0012 0.0181
betacellulin, epidermal growth factor family member Btc 1.6 0.0006 0.0119
cellular nucleic acid binding protein Cnbp 1.6 0.0003 0.0083
lectin, galactoside binding-like Lgalsl 1.6 2.51E-06 0.0005
A kinase (PRKA) anchor protein 13 Akap13 1.6 0.0007 0.0131
fatty acyl CoA reductase 1 Far1 1.6 4.21E-05 0.0025
kinesin family member 13A Kif13a 1.59 2.94E-05 0.002
predicted gene, 33916 Gm33916 1.59 0.0006 0.0118
1.59 0.0005 0.0107
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide Ywhae 1.59 7.51E-05 0.0035
PTK2 protein tyrosine kinase 2 Ptk2 1.59 0.0063 0.049
RAD21 homolog (S. pombe) Rad21 1.59 3.99E-05 0.0024
chromobox 1 Cbx1 1.59 1.96E-09 2.59E-05
cancer susceptibility candidate 5 Casc5 1.59 6.77E-05 0.0033
solute carrier organic anion transporter family, member 1a5 Slco1a5 1.59 0.0002 0.0064
chromodomain helicase DNA binding protein 4 Chd4 1.59 0.0001 0.0043
transmembrane protein with EGF-like and two follistatin-like domains 1 Tmeff1 1.59 4.05E-06 0.0007
leucine rich repeat containing 58 Lrrc58 1.59 6.65E-06 0.0008
family with sequence similarity 43, member A Fam43a 1.59 2.23E-05 0.0017
pseudopodium-enriched atypical kinase 1 Peak1 1.58 0.0002 0.0066
phosphatidylinositol 4-kinase type 2 beta Pi4k2b 1.58 0.0003 0.0078
heat shock protein 4 Hspa4 1.58 2.59E-06 0.0005
poly (ADP-ribose) polymerase family, member 3 Parp3 1.58 0.0002 0.007
DENN/MADD domain containing 5B Dennd5b 1.58 2.12E-05 0.0016
transmembrane protein 123 Tmem123 1.58 8.16E-05 0.0037
STT3, subunit of the oligosaccharyltransferase complex, homolog A (S. cerevisiae) Stt3a 1.58 6.01E-08 9.33E-05
guanine nucleotide binding protein, alpha q polypeptide Gnaq 1.58 0.0002 0.0054
1.58 0.0008 0.0141
RAS p21 protein activator 1 Rasa1 1.58 3.22E-08 5.80E-05
WD repeat and FYVE domain containing 1 Wdfy1 1.58 6.26E-06 0.0008
additional sex combs like 2 (Drosophila) Asxl2 1.58 0.0005 0.011
zinc finger protein 942 Zfp942 1.58 0.0054 0.0445
1.57 0.0007 0.0131
ethanolamine kinase 1 Etnk1 1.57 1.51E-05 0.0014
predicted pseudogene 8203; H2A histone family, member Z Gm8203; H2afz 1.57 0.0007 0.0134
ubiquitin specific peptidase 48 Usp48 1.57 8.21E-06 0.0009
general transcription factor III C 1 Gtf3c1 1.57 0.0005 0.0111
1.57 0.0024 0.0269
methyltransferase like 9 Mettl9 1.57 9.78E-05 0.0041
ubiquitin specific peptidase 25 Usp25 1.57 0.0004 0.0093
1.57 9.70E-05 0.0041
RNA binding motif protein 26 Rbm26 1.57 2.28E-05 0.0017
vasorin Vasn 1.56 0.0002 0.0064
Rho guanine nucleotide exchange factor (GEF) 12 Arhgef12 1.56 0.0059 0.0469
DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 Ddx21 1.56 0.0002 0.0065
tumor necrosis factor alpha induced protein 6 Tnfaip6 1.56 0.0017 0.0223
elongation factor RNA polymerase II 2 Ell2 1.56 1.06E-06 0.0004
far upstream element (FUSE) binding protein 1 Fubp1 1.56 0.0002 0.0055




PDZ and LIM domain 5 Pdlim5 1.56 1.17E-07 0.0001
laminin, gamma 1 Lamc1 1.55 3.48E-06 0.0006
neutral cholesterol ester hydrolase 1 Nceh1 1.55 0.0002 0.006
TGF-beta1-induced anti-apoptotic factor 2 Tiaf2 1.55 1.93E-05 0.0015
jagged 1 Jag1 1.55 9.77E-08 0.0001
surfeit gene 4 Surf4 1.55 1.83E-06 0.0005
ring finger protein, transmembrane 1 Rnft1 1.55 1.58E-06 0.0004
zinc finger protein 141 Zfp141 1.55 0.0003 0.0089
tropomyosin 1, alpha Tpm1 1.55 0.0003 0.0086
minichromosome maintenance deficient 4 homolog (S. cerevisiae) Mcm4 1.55 0.0005 0.011
GRIP and coiled-coil domain containing 2 Gcc2 1.55 1.07E-05 0.0011
tetratricopeptide repeat domain 3 Ttc3 1.55 5.33E-07 0.0003
TAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor Taf1 1.55 2.71E-06 0.0006
eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein) Eef1d 1.55 2.43E-06 0.0005
GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus Gnas 1.55 0.0005 0.0107
suppressor of Ty 16 Supt16 1.55 6.26E-05 0.0032
sprouty homolog 4 (Drosophila) Spry4 1.55 7.02E-05 0.0034
40S ribosomal protein S6; ribosomal protein S6 LOC105244208; Rps6 1.54 1.16E-05 0.0012
protein phosphatase 1A, magnesium dependent, alpha isoform Ppm1a 1.54 5.08E-05 0.0028
procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha II polypeptide P4ha2 1.54 0.0002 0.0056
solute carrier family 5 (inositol transporters), member 3 Slc5a3 1.54 4.18E-05 0.0025
CAP-GLY domain containing linker protein 1 Clip1 1.54 4.04E-06 0.0007
solute carrier family 39 (metal ion transporter), member 6 Slc39a6 1.54 4.16E-05 0.0025
forty-two-three domain containing 1 Fyttd1 1.54 9.54E-05 0.0041
leucine-rich repeat kinase 2 Lrrk2 1.54 9.92E-06 0.0011
transcription factor 4 Tcf4 1.54 0.0001 0.0049
fibroblast growth factor receptor 1 Fgfr1 1.54 0.0038 0.0364
translocase of outer mitochondrial membrane 7 homolog (yeast) Tomm7 1.54 0.0002 0.0073
Rap1 interacting factor 1 homolog (yeast) Rif1 1.54 6.84E-05 0.0033
lysine (K)-specific methyltransferase 2E Kmt2e 1.54 6.49E-07 0.0003
limb-bud and heart Lbh 1.53 0.0003 0.0077
spermatogenesis associated 13 Spata13 1.53 1.60E-05 0.0014
unc-5 homolog B (C. elegans) Unc5b 1.53 0.0016 0.0213
latent transforming growth factor beta binding protein 3 Ltbp3 1.53 8.94E-05 0.0039
LIM domain containing preferred translocation partner in lipoma Lpp 1.53 5.54E-07 0.0003
zinc finger and BTB domain containing 38 Zbtb38 1.53 2.54E-06 0.0005
RIKEN cDNA 4930503L19 gene 4930503L19Rik 1.53 0.0002 0.0054
Rho-related BTB domain containing 3 Rhobtb3 1.53 0.0004 0.0089
LYR motif containing 5 Lyrm5 1.53 0.0004 0.0094
chaperonin containing Tcp1, subunit 2 (beta) Cct2 1.53 2.18E-06 0.0005
gastrokine 3 Gkn3 1.53 0.0026 0.0287
transmembrane protein 30A Tmem30a 1.53 1.05E-06 0.0004
collagen, type XVIII, alpha 1 Col18a1 1.53 1.01E-05 0.0011
fibronectin leucine rich transmembrane protein 3 Flrt3 1.53 0.0046 0.0407
ubiquitin-conjugating enzyme E2D 2A Ube2d2a 1.53 1.21E-05 0.0012
1.53 7.33E-05 0.0034
1.52 0.0025 0.028
40S ribosomal protein S6; ribosomal protein S6 LOC105244208; Rps6 1.52 1.70E-05 0.0014
paired related homeobox 1 Prrx1 1.52 0.0005 0.0103
bromodomain adjacent to zinc finger domain, 1B Baz1b 1.52 0.0004 0.009
UDP-GalNAc:betaGlcNAc beta 1,3-galactosaminyltransferase, polypeptide 2 B3galnt2 1.52 9.55E-05 0.0041
acyl-CoA synthetase long-chain family member 6 Acsl6 1.52 0.0001 0.0042
DnaJ (Hsp40) homolog, subfamily C, member 1 Dnajc1 1.52 2.03E-05 0.0016
regulator of G-protein signaling 5 Rgs5 1.52 0.0017 0.0224
PDZ and LIM domain 4 Pdlim4 1.52 0.0004 0.0093
notch 4 Notch4 1.52 0.0003 0.0076
GLI-Kruppel family member GLI2 Gli2 1.52 0.0007 0.0127
Rap guanine nucleotide exchange factor (GEF) 3 Rapgef3 1.52 0.0003 0.0077
ubiquitin protein ligase E3 component n-recognin 5 Ubr5 1.52 0.0003 0.0074
solute carrier family 41, member 1 Slc41a1 1.51 0.0006 0.0121
neurobeachin like 1 Nbeal1 1.51 4.93E-06 0.0007
proline arginine-rich end leucine-rich repeat Prelp 1.51 0.001 0.0157
dedicator of cytokinesis 9 Dock9 1.51 3.15E-05 0.0021
G-rich RNA sequence binding factor 1 Grsf1 1.51 1.33E-06 0.0004
serine/arginine-rich splicing factor 7 Srsf7 1.51 3.47E-05 0.0022
transmembrane protein with EGF-like and two follistatin-like domains 1 Tmeff1 1.51 0.0005 0.0113
zinc finger protein 407 Zfp407 1.51 0.0005 0.0103
predicted gene 21992; RNA binding motif protein 4 Gm21992; Rbm4 1.51 0.0015 0.0203
expressed sequence AI662270 AI662270 1.51 0.0001 0.0043
Janus kinase 1 Jak1 1.51 2.87E-06 0.0006
intersectin 2 Itsn2 1.51 1.14E-05 0.0012
telomeric repeat binding factor 1 Terf1 1.51 0.0031 0.0321
sterol carrier protein 2, liver Scp2 1.51 0.0005 0.0107
bromodomain adjacent to zinc finger domain, 2A Baz2a 1.51 0.0011 0.0173
regulator of cell cycle Rgcc 1.51 0.0026 0.0287
serine/arginine-rich protein specific kinase 2 Srpk2 1.51 0.0003 0.0082
Rho guanine nucleotide exchange factor (GEF) 12 Arhgef12 1.51 3.37E-06 0.0006
canopy 2 homolog (zebrafish) Cnpy2 1.51 1.36E-07 0.0001
mitogen-activated protein kinase kinase kinase 12 Map3k12 1.51 7.72E-08 0.0001
dedicator of cytokinesis 7 Dock7 1.51 3.41E-05 0.0022
SCY1-like 1 (S. cerevisiae) Scyl1 1.51 0.0001 0.0046
DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 Ddx6 1.51 0.0002 0.0054
1.51 0.0026 0.0286
heat shock protein 5 Hspa5 1.5 5.11E-06 0.0007
F-box protein 32 Fbxo32 1.5 0.0031 0.0322
fibroblast growth factor 11 Fgf11 1.5 0.0019 0.0234
ornithine decarboxylase, structural 1 pseudogene; ornithine decarboxylase, structural 1 Gm9115; Odc1 1.5 3.81E-05 0.0023
inositol polyphosphate-5-phosphatase F Inpp5f 1.5 1.12E-05 0.0012
1.5 0.0001 0.0051
parvin, beta Parvb 1.5 0.004 0.0373
centrosomal protein 170 Cep170 1.5 0.0006 0.012
-1.5 0.0033 0.0333
ribonucleotide reductase M2 Rrm2 -1.5 2.49E-07 0.0002
ATR interacting protein; three prime repair exonuclease 1 Atrip; Trex1 -1.5 0.0004 0.01
cDNA sequence BC038331 BC038331 -1.51 1.72E-05 0.0014
hydroxyacylglutathione hydrolase-like Haghl -1.51 4.71E-05 0.0027
splicing factor 3a, subunit 1 Sf3a1 -1.51 1.38E-06 0.0004
slowmo homolog 1 (Drosophila) Slmo1 -1.51 0.0003 0.0083
cannabinoid receptor 2 (macrophage) Cnr2 -1.51 0.0044 0.0393
RIKEN cDNA 2010109A12 gene 2010109A12Rik -1.51 1.36E-06 0.0004
-1.51 0.0054 0.0445
Fas ligand (TNF superfamily, member 6) Fasl -1.52 1.48E-05 0.0013
CD28 antigen Cd28 -1.52 0.0016 0.0212
serine (or cysteine) peptidase inhibitor, clade B, member 9 Serpinb9 -1.52 0.0014 0.0194
tripartite motif-containing 5 Trim5 -1.52 0.0051 0.0433
mitochondrial carrier homolog 2 (C. elegans) Mtch2 -1.52 1.19E-05 0.0012
G protein-coupled receptor 68 Gpr68 -1.52 5.46E-05 0.0029
proline-serine-threonine phosphatase-interacting protein 1 Pstpip1 -1.52 0.0013 0.0192
coagulation factor VII F7 -1.52 0.0017 0.0225
ajuba LIM protein Ajuba -1.52 2.95E-05 0.002
ubiquitin-conjugating enzyme E2Q family-like 1 Ube2ql1 -1.52 6.60E-06 0.0008
RAS protein activator like 3 Rasal3 -1.53 0.004 0.0376
-1.53 0.0004 0.0095
dual adaptor for phosphotyrosine and 3-phosphoinositides 1 Dapp1 -1.53 1.50E-06 0.0004
RIKEN cDNA I830077J02 gene I830077J02Rik -1.53 0.0001 0.0044
-1.53 0.0008 0.0145
zinc finger, DHHC domain containing 14 Zdhhc14 -1.53 0.0017 0.0221
-1.53 0.0058 0.0466
-1.53 0.0003 0.0079
toll-like receptor 2 Tlr2 -1.54 0.0007 0.0127
myosin IF Myo1f -1.54 0.0005 0.0104
protein kinase C, eta Prkch -1.54 0.0011 0.0175
sphingomyelin phosphodiesterase 4 Smpd4 -1.54 1.21E-05 0.0012
RWD domain containing 1 Rwdd1 -1.54 0.0002 0.0061
DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 Ddx4 -1.54 0.001 0.016
-1.54 0.002 0.0241
phosphoinositide-3-kinase adaptor protein 1 Pik3ap1 -1.54 0.0003 0.0078
allograft inflammatory factor 1-like Aif1l -1.54 2.12E-05 0.0016
allograft inflammatory factor 1-like Aif1l -1.55 0.0001 0.0045
RIKEN cDNA 5730508B09 gene 5730508B09Rik -1.55 0.0002 0.0065
CASP8 and FADD-like apoptosis regulator Cflar -1.55 0.0002 0.006
RIKEN cDNA 5730508B09 gene 5730508B09Rik -1.55 0.0001 0.0048
DNA segment, Chr 13, ERATO Doi 608, expressed D13Ertd608e -1.55 0.0013 0.0191
ribonuclease, RNase A family, 2A (liver, eosinophil-derived neurotoxin) Rnase2a -1.55 0.001 0.0164
pleckstrin homology domain containing, family F (with FYVE domain) member 2 Plekhf2 -1.56 9.75E-07 0.0003
cytotoxic and regulatory T cell molecule Crtam -1.56 0.0051 0.0431
lysophosphatidylcholine acyltransferase 2 Lpcat2 -1.56 0.0006 0.0124
src-like adaptor Sla -1.56 0.0058 0.0466
chemokine (C-X-C motif) ligand 11 Cxcl11 -1.57 0.0016 0.0215
transferrin receptor Tfrc -1.57 1.75E-05 0.0015
interleukin 15 Il15 -1.57 0.0011 0.0166
RIKEN cDNA 6330407A03 gene 6330407A03Rik -1.57 0.0029 0.0305
lymphocyte cytosolic protein 1 Lcp1 -1.57 0.0037 0.0359
phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 Prex1 -1.57 0.0004 0.0093
low density lipoprotein receptor-related protein associated protein 1 Lrpap1 -1.57 0.0007 0.0132
adiponectin receptor 1 Adipor1 -1.57 3.24E-09 2.59E-05
myeloblastosis oncogene-like 2 Mybl2 -1.57 8.99E-07 0.0003
CD274 antigen Cd274 -1.57 0.0045 0.0398
coiled-coil domain containing 69 Ccdc69 -1.58 0.0019 0.0233
Mediterranean fever Mefv -1.58 1.27E-05 0.0012
DENN/MADD domain containing 1C Dennd1c -1.58 0.0032 0.0325
RIKEN cDNA 4833438C02 gene 4833438C02Rik -1.58 7.96E-08 0.0001
small nuclear ribonucleoprotein D3 Snrpd3 -1.58 3.45E-09 2.59E-05
Rho GTPase activating protein 25 Arhgap25 -1.58 0.0062 0.0487
coronin, actin binding protein 1A Coro1a -1.58 0.0053 0.0441
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 -1.58 0.0047 0.0409
prolactin family 2, subfamily b, member 1 Prl2b1 -1.58 5.20E-06 0.0007
megakaryocyte-associated tyrosine kinase Matk -1.59 7.51E-06 0.0009
membrane-spanning 4-domains, subfamily A, member 7 Ms4a7 -1.59 0.0012 0.0177
RasGEF domain family, member 1B Rasgef1b -1.59 0.0003 0.0086
Z-DNA binding protein 1 Zbp1 -1.59 0.0062 0.0488
membrane-spanning 4-domains, subfamily A, member 4C Ms4a4c -1.59 0.0011 0.0172
unc-93 homolog B1 (C. elegans) Unc93b1 -1.59 0.0049 0.0423
-1.6 0.001 0.016
chemokine (C-X-C motif) ligand 16 Cxcl16 -1.6 1.93E-06 0.0005
histone cluster 1, H1c Hist1h1c -1.6 0.0001 0.0049
coiled-coil domain containing 88B Ccdc88b -1.6 6.28E-05 0.0032
tumor necrosis factor receptor superfamily, member 4 Tnfrsf4 -1.6 7.69E-07 0.0003
TAP binding protein-like Tapbpl -1.61 0.0003 0.0077
high mobility group AT-hook 2, pseudogene 1 Hmga2-ps1 -1.61 0.0003 0.008
phosphotyrosine interaction domain containing 1 Pid1 -1.61 4.39E-05 0.0026
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 Galnt6 -1.61 0.0039 0.037
interleukin 7 Il7 -1.61 0.0006 0.0122
ectonucleoside triphosphate diphosphohydrolase 1 Entpd1 -1.62 0.0039 0.0366
regulator of G-protein signaling 1 Rgs1 -1.62 0.0043 0.039
proteasome (prosome, macropain) subunit, beta type 10 Psmb10 -1.62 0.0001 0.0048
splicing factor 1 Sf1 -1.63 7.68E-06 0.0009
FYVE, RhoGEF and PH domain containing 2 Fgd2 -1.63 0.0012 0.0182
leukocyte-associated Ig-like receptor 1 Lair1 -1.63 0.0051 0.0433
phosphatidylinositol-specific phospholipase C, X domain containing 2 Plcxd2 -1.63 1.99E-05 0.0016
chemokine (C-X-C motif) ligand 16 Cxcl16 -1.64 0.0001 0.005
src-like adaptor Sla -1.64 0.0004 0.0097
-1.65 0.0002 0.0068
ubiquitin-like modifier activating enzyme 7 Uba7 -1.65 0.0031 0.0323
muscleblind-like 3 (Drosophila) Mbnl3 -1.65 1.00E-05 0.0011
Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog Fgr -1.65 5.03E-05 0.0028
hydroxyacylglutathione hydrolase-like Haghl -1.65 1.35E-05 0.0013
-1.65 0.0034 0.0337
NEDD4 binding protein 2-like 1 N4bp2l1 -1.65 2.20E-05 0.0016
epithelial stromal interaction 1 (breast) Epsti1 -1.66 0.0027 0.0293
killer cell lectin-like receptor, subfamily A, member 7; killer cell lectin-like receptor 7 Klra7; LOC100862438 -1.66 0.0017 0.022
Fc receptor, IgG, high affinity I Fcgr1 -1.66 0.0015 0.0205
transmembrane protein 238 Tmem238 -1.66 2.32E-08 5.13E-05
arrestin domain containing 4 Arrdc4 -1.66 0.0001 0.005
interleukin 18 binding protein Il18bp -1.66 0.0025 0.0276
killer cell lectin-like receptor subfamily A, member 21; killer cell lectin-like receptor, subfamily A, member 3; killer cell lectin-like receptor, subfamily A, member 8Kl a21; Kl a3; Klra8 -1.67 1.70E-05 0.0014
nuclear receptor subfamily 4, group A, member 3 Nr4a3 -1.67 2.73E-06 0.0006
basic leucine zipper transcription factor, ATF-like 3 Batf3 -1.67 0.0004 0.009
toll-like receptor 8 Tlr8 -1.69 0.006 0.0476
membrane-spanning 4-domains, subfamily A, member 7 Ms4a7 -1.69 0.0005 0.0104
-1.69 1.03E-06 0.0004
interleukin 1 receptor antagonist Il1rn -1.7 0.0002 0.0072
phosphoinositide-3-kinase adaptor protein 1 Pik3ap1 -1.7 0.0022 0.0254
interferon regulatory factor 5 Irf5 -1.7 0.0045 0.0398
histocompatibility 2, class II, locus Mb1; histocompatibility 2, class II, locus Mb2 H2-DMb1; H2-DMb2 -1.71 0.0054 0.0445
class II transactivator Ciita -1.71 0.001 0.0165
inducible T cell co-stimulator Icos -1.71 0.0001 0.0043
cDNA sequence AF251705 AF251705 -1.71 0.0032 0.0327
interleukin 1 receptor antagonist Il1rn -1.72 0.0002 0.0056
syndecan 3 Sdc3 -1.72 0.0043 0.0391
neutrophil cytosolic factor 4 Ncf4 -1.72 0.0014 0.02
adhesion G protein-coupled receptor E4 Adgre4 -1.72 0.0039 0.0372
allograft inflammatory factor 1-like Aif1l -1.72 0.0002 0.0068
expressed sequence AI504432 AI504432 -1.72 0.0013 0.0193
RAS guanyl releasing protein 1 Rasgrp1 -1.73 0.0011 0.0167
Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog Fgr -1.73 0.0019 0.0238
adrenergic receptor kinase, beta 2 Adrbk2 -1.73 0.0005 0.0104
C-type lectin domain family 5, member a Clec5a -1.73 0.0008 0.0141
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, delta Nfkbid -1.74 2.62E-05 0.0019
myeloblastosis oncogene Myb -1.74 0.0031 0.0317
uncharacterized LOC105247125 LOC105247125 -1.74 0.002 0.0244
-1.75 0.0001 0.0045
regulator of G-protein signaling 2 Rgs2 -1.75 0.0021 0.0247
apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 Apobec1 -1.75 0.0004 0.0093
signal-regulatory protein alpha Sirpa -1.76 0.0002 0.0071
transmembrane protein 106A Tmem106a -1.76 0.0058 0.0467
neutrophil cytosolic factor 2 Ncf2 -1.76 0.0052 0.0436
coronin, actin binding protein 1A Coro1a -1.76 0.0031 0.0322
predicted gene, 37416; predicted gene, 39743; predicted gene, 40611; predicted gene, 40814; predicted gene, 41035; predicted gene, 41476; uncharacterized LOC105244034Gm37416; Gm39743; Gm40611; Gm40814; Gm41035; Gm4 476; LOC105244034- .76 8.81E-06 0.001
membrane-spanning 4-domains, subfamily A, member 6C Ms4a6c -1.77 0.0032 0.0325
Fas ligand (TNF superfamily, member 6) Fasl -1.77 0.0006 0.0114
interleukin 2 receptor, beta chain Il2rb -1.77 2.66E-05 0.0019
histocompatibility 2, Q region locus 6; histocompatibility 2, Q region locus 8; histocompatibility 2, Q region locus 6-likeH2-Q6; H2-Q8; LOC68395 -1.77 0.0064 0.05
elongation protein 4 homolog (S. cerevisiae) Elp4 -1.77 2.67E-05 0.0019
CD300 antigen like family member F Cd300lf -1.77 0.0005 0.0103
coronin, actin binding protein 2A Coro2a -1.77 0.0004 0.0102
cystatin F (leukocystatin) Cst7 -1.77 0.001 0.0166
hemopoietic cell kinase Hck -1.78 0.0052 0.0437
SH2 domain containing 1B1; SH2 domain containing 1B2 Sh2d1b1; Sh2d1b2 -1.78 0.0047 0.0411
retinol dehydrogenase 16; retinol dehydrogenase 18, pseudogene Rdh16; Rdh18-ps -1.78 0.0002 0.006
TRAF-interacting protein with forkhead-associated domain, family member B Tifab -1.78 0.0011 0.0173
allograft inflammatory factor 1 Aif1 -1.79 0.0059 0.0472
macrophage expressed gene 1 Mpeg1 -1.81 0.0014 0.02
G-protein coupled receptor 65 Gpr65 -1.81 0.0042 0.0386
C-type lectin domain family 4, member a3 Clec4a3 -1.81 0.0042 0.0382
runt related transcription factor 3 Runx3 -1.81 0.0001 0.0043
inducible T cell co-stimulator Icos -1.81 0.0003 0.0079
SAM and SH3 domain containing 3 Sash3 -1.82 0.0041 0.0382
-1.82 0.0005 0.0104
lymphocyte cytosolic protein 2 Lcp2 -1.83 0.0052 0.0438
C-type lectin domain family 4, member a2 Clec4a2 -1.83 0.0049 0.0422
membrane-spanning 4-domains, subfamily A, member 6B Ms4a6b -1.83 0.0045 0.0402
nudix (nucleoside diphosphate linked moiety X)-type motif 21 Nudt21 -1.83 0.0039 0.0371
complement component 3a receptor 1 C3ar1 -1.83 0.0002 0.0062
G protein-coupled receptor 171 Gpr171 -1.84 0.0025 0.0277
hydroxyacylglutathione hydrolase-like Haghl -1.84 2.52E-06 0.0005
spleen focus forming virus (SFFV) proviral integration oncogene Spi1 -1.84 0.0043 0.039
inducible T cell co-stimulator Icos -1.84 0.0005 0.0111
NLR family, apoptosis inhibitory protein 5 Naip5 -1.84 0.0007 0.0134
signal-regulatory protein beta 1-like; signal-regulatory protein beta 1A; signal-regulatory protein beta 1BLOC100038947; Sirpb1a; Sirpb1b -1.84 0.0005 0.0106
immunoresponsive gene 1 Irg1 -1.84 0.0053 0.0441
interleukin 7 receptor Il7r -1.85 0.0021 0.0247
signal-regulatory protein alpha Sirpa -1.85 0.0057 0.0459
G protein-coupled receptor 18 Gpr18 -1.85 0.0019 0.0237
-1.86 0.0004 0.0091
programmed cell death 1 ligand 2 Pdcd1lg2 -1.86 0.001 0.0158
tumor suppressor candidate 1 Tusc1 -1.86 0.0005 0.0113
T cell receptor beta, joining region Tcrb-J -1.86 0.0023 0.0262
G protein-coupled receptor 183 Gpr183 -1.87 0.0012 0.0184
CD52 antigen Cd52 -1.87 0.0013 0.0189
transferrin receptor Tfrc -1.87 1.33E-06 0.0004
Fc receptor, IgG, high affinity I Fcgr1 -1.87 0.0031 0.0319
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 B3gnt5 -1.87 0.0053 0.0439
ATPase, class I, type 8B, member 4 Atp8b4 -1.87 0.0053 0.0444
cathepsin W Ctsw -1.87 1.89E-06 0.0005
-1.88 0.0037 0.0359
adrenergic receptor kinase, beta 2 Adrbk2 -1.89 0.0006 0.0119
interleukin 2 receptor, beta chain Il2rb -1.89 1.14E-05 0.0012
CD86 antigen Cd86 -1.89 0.0007 0.0133
leukocyte-associated Ig-like receptor 1 Lair1 -1.89 0.0011 0.0176
src-like adaptor Sla -1.9 0.0011 0.0175
signal-regulatory protein beta 1-like; signal-regulatory protein beta 1A; signal-regulatory protein beta 1BLOC100038947; Sirpb1a; Sirpb1b -1.9 0.0015 0.0202
solute carrier family 15, member 3 Slc15a3 -1.9 0.0007 0.0127
histocompatibility 2, class II, locus DMa H2-DMa -1.9 0.003 0.031
Ras association (RalGDS/AF-6) domain family member 5 Rassf5 -1.91 0.0012 0.0182
T cell receptor alpha variable 9D-3 Trav9d-3 -1.92 0.001 0.0161
fermitin family homolog 3 (Drosophila) Fermt3 -1.92 0.0037 0.0354
lymphocyte specific 1 Lsp1 -1.93 0.0025 0.028
hydroxysteroid 11-beta dehydrogenase 1 Hsd11b1 -1.93 0.0011 0.0175
IL2 inducible T cell kinase Itk -1.93 0.002 0.0243
uncharacterized LOC105247125 LOC105247125 -1.93 0.0049 0.0422
killer cell lectin-like receptor subfamily B member 1F Klrb1f -1.93 1.11E-06 0.0004
Wiskott-Aldrich syndrome homolog (human) Was -1.94 0.0012 0.018
predicted pseudogene 10693; predicted gene 14548; leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 6; paired-Ig-like receptor A1; paired-Ig-like receptor A11; paired-Ig-like receptor A2; paired-Ig-like receptor A4; paired-Ig-like receptor A5; paired-Ig-like receptor A6; paired-Ig-like receptor A7; paired Ig-like receptor BGm10693; Gm14548; Lilra6; Pira1; Pira11; Pira2; Pira4; P a5; Pira6; Pira7; Pirb-1.94 0.0015 0.0205
SLAM family member 7 Slamf7 -1.94 7.93E-05 0.0036
signal-regulatory protein alpha Sirpa -1.94 0.0001 0.0048
-1.95 0.0003 0.0083
coagulation factor X F10 -1.96 4.98E-05 0.0027
leupaxin Lpxn -1.96 0.0012 0.0183
protein tyrosine phosphatase, receptor type, O Ptpro -1.96 0.0002 0.0067
Fc receptor, IgE, high affinity I, gamma polypeptide Fcer1g -1.97 0.0014 0.02
interleukin 18 receptor 1 Il18r1 -1.97 8.33E-05 0.0037
paired-Ig-like receptor A1; paired-Ig-like receptor A2; paired-Ig-like receptor A6 Pira1; Pira2; Pira6 -1.97 3.72E-05 0.0023
phosphoinositide-3-kinase, regulatory subunit 6 Pik3r6 -1.97 0.002 0.024
chemokine (C-C motif) receptor 5 Ccr5 -1.98 0.0035 0.0346
killer cell lectin-like receptor, subfamily A, member 2 Klra2 -1.98 0.0031 0.0321
chemokine (C-X-C motif) ligand 9 Cxcl9 -2 0.0032 0.0326


































hematopoietic cell specific Lyn substrate 1 Hcls1 -2 0.0014 0.02
GM2 ganglioside activator protein Gm2a -2 0.0058 0.0465
CD300A antigen Cd300a -2.01 0.0036 0.0348
lymphocyte protein tyrosine kinase Lck -2.01 0.0003 0.0084
mitogen-activated protein kinase-activated protein kinase 3 Mapkapk3 -2.01 0.0008 0.0146
tumor necrosis factor receptor superfamily, member 18 Tnfrsf18 -2.02 1.13E-05 0.0012
interleukin 7 receptor Il7r -2.02 9.63E-05 0.0041
histocompatibility 2, class II antigen E beta H2-Eb1 -2.03 0.0043 0.0391
phospholipase D family, member 4 Pld4 -2.03 0.0042 0.0382
selectin, platelet (p-selectin) ligand Selplg -2.04 0.0019 0.0234
T-cell receptor beta-2 chain C region-like; T cell receptor beta, constant 2 LOC665506; Trbc2 -2.04 0.0046 0.0408
GTPase, IMAP family member 7 Gimap7 -2.04 0.0029 0.0306
CD209a antigen Cd209a -2.04 0.0031 0.0318
cytotoxic T-lymphocyte-associated protein 4 Ctla4 -2.05 4.58E-06 0.0007
signal transducer and activator of transcription 4 Stat4 -2.06 0.0001 0.0053
interleukin 10 receptor, alpha Il10ra -2.06 0.0001 0.0048
T-cell receptor beta-2 chain C region-like; T cell receptor beta, joining region; T cell receptor beta, constant region 1; T cell receptor beta, constant 2LOC665506; Tcrb-J; Trbc1; Trbc2 -2.06 0.0049 0.042
CD8 antigen, alpha chain Cd8a -2.06 0.0045 0.0399
cytochrome P450, family 4, subfamily f, polypeptide 18 Cyp4f18 -2.06 0.0005 0.011
protein tyrosine phosphatase, non-receptor type 22 (lymphoid) Ptpn22 -2.06 0.0011 0.0167
toll-like receptor 7 Tlr7 -2.06 0.0038 0.0363
mast cell immunoglobulin like receptor 1 Milr1 -2.07 6.74E-05 0.0033
ecotropic viral integration site 2b; predicted gene 21975 Evi2b; Gm21975 -2.08 0.0014 0.02
CD83 antigen Cd83 -2.08 1.58E-05 0.0014
expressed sequence AI504432 AI504432 -2.08 0.0004 0.0097
C-type lectin domain family 4, member a2; C-type lectin domain family 4, member b1 Clec4a2; Clec4b1 -2.09 0.0011 0.0172
cytohesin 1 interacting protein Cytip -2.09 0.0025 0.0279
myosin IG Myo1g -2.11 0.0057 0.0462
CD3 antigen, delta polypeptide Cd3d -2.12 0.0028 0.0301
RAB27A, member RAS oncogene family Rab27a -2.13 0.0002 0.0063
expressed sequence AW112010 AW112010 -2.15 0.0015 0.0206
phosphoinositide-3-kinase, regulatory subunit 5, p101 Pik3r5 -2.16 0.0013 0.0186
protein tyrosine phosphatase, receptor type, C Ptprc -2.16 0.0031 0.0318
cDNA sequence AB124611 AB124611 -2.17 0.0056 0.0455
TRAF-interacting protein with forkhead-associated domain, family member B Tifab -2.17 0.0002 0.0053
-2.17 0.0011 0.0176
B cell leukemia/lymphoma 2 related protein A1a; B cell leukemia/lymphoma 2 related protein A1b; B cell leukemia/lymphoma 2 related protein A1dBcl2a1a; Bcl2a1b; Bcl2a1d -2.17 0.0001 0.0047
tumor necrosis factor receptor superfamily, member 13b Tnfrsf13b -2.18 0.0063 0.0493
T cell receptor alpha constant Trac -2.18 0.0012 0.0177
CD2 antigen Cd2 -2.19 0.0019 0.0234
CD86 antigen Cd86 -2.2 0.0002 0.0072
CD300 molecule-like family member d Cd300ld -2.21 0.0022 0.0258
mago-nashi homolog B (Drosophila) Magohb -2.21 0.0053 0.0439
chemokine (C-X-C motif) receptor 6 Cxcr6 -2.22 0.0034 0.0338
C-type lectin domain family 4, member a2 Clec4a2 -2.23 5.94E-06 0.0008
formyl peptide receptor 2 Fpr2 -2.24 0.004 0.0374
protein tyrosine phosphatase, receptor type, O Ptpro -2.24 1.64E-05 0.0014
SLAM family member 9 Slamf9 -2.24 0.0005 0.0109
preproenkephalin Penk -2.24 0.0022 0.0254
purinergic receptor P2Y, G-protein coupled, 14 P2ry14 -2.25 0.0006 0.0114
-2.26 0.0025 0.0282
immunoglobulin superfamily, member 6 Igsf6 -2.26 0.0002 0.0072
phospholipase B domain containing 1 Plbd1 -2.26 0.0002 0.0055
killer cell lectin-like receptor subfamily B member 1B Klrb1b -2.27 0.001 0.0157
myosin IF Myo1f -2.27 0.0019 0.0235
histocompatibility 2, class II antigen A, beta 1 H2-Ab1 -2.27 0.0016 0.0213
leukocyte-associated Ig-like receptor 1 Lair1 -2.28 0.0004 0.009
cytochrome b-245, beta polypeptide Cybb -2.28 0.0018 0.0229
CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) Cd74 -2.28 0.0023 0.0266
histocompatibility 2, class II antigen A, alpha H2-Aa -2.28 0.0023 0.0263
membrane-associated ring finger (C3HC4) 1 1-Mar -2.29 0.006 0.0478
histocompatibility 2, class II antigen A, beta 1 H2-Ab1 -2.3 0.0013 0.0187
chemokine (C-C motif) receptor 1 Ccr1 -2.3 0.0046 0.0407
schlafen 1 Slfn1 -2.32 4.11E-05 0.0025
T-cell receptor beta-2 chain C region-like; T cell receptor beta, constant 2 LOC665506; Trbc2 -2.32 0.0047 0.0409
killer cell lectin-like receptor subfamily B member 1B Klrb1b -2.35 0.0004 0.0092
chemokine (C-C motif) receptor 2 Ccr2 -2.36 0.0004 0.0097
membrane-spanning 4-domains, subfamily A, member 4B Ms4a4b -2.36 0.0018 0.0232
guanylate-binding protein 8 Gbp8 -2.37 0.0028 0.0299
Ras association (RalGDS/AF-6) domain family member 2 Rassf2 -2.37 0.0038 0.0363
Fc receptor, IgG, low affinity IV Fcgr4 -2.4 0.0031 0.0319
hepatitis A virus cellular receptor 2 Havcr2 -2.42 4.63E-06 0.0007
natural killer cell group 7 sequence Nkg7 -2.48 0.0004 0.0095
histocompatibility 2, class II antigen A, beta 1 H2-Ab1 -2.49 0.0014 0.02
histocompatibility 2, class II antigen A, alpha H2-Aa -2.52 0.0023 0.0264
colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) Csf2ra -2.52 0.0051 0.0434
granzyme B Gzmb -2.55 5.23E-05 0.0028
family with sequence similarity 26, member F Fam26f -2.59 0.0012 0.0184
killer cell lectin-like receptor subfamily B member 1B Klrb1b -2.6 0.0006 0.0114
SLAM family member 8 Slamf8 -2.62 0.0004 0.0096
T cell receptor alpha constant Trac -2.66 0.0016 0.0212
chemokine (C-C motif) receptor 2 Ccr2 -2.7 0.0037 0.0356
C-type lectin domain family 7, member a Clec7a -2.71 5.45E-05 0.0029
serine (or cysteine) peptidase inhibitor, clade A, member 3G Serpina3g -2.78 0.0011 0.017
CD3 antigen, gamma polypeptide Cd3g -2.9 0.002 0.0246
killer cell lectin-like receptor subfamily K, member 1 Klrk1 -2.91 1.18E-06 0.0004
killer cell lectin-like receptor, subfamily A, member 3; killer cell lectin-like receptor subfamily A, member 9Klra3; Klra9 -2.94 1.04E-05 0.0011
secreted and transmembrane 1A Sectm1a -2.96 2.19E-05 0.0016
killer cell lectin-like receptor, subfamily D, member 1 Klrd1 -3.23 0.0003 0.0079
killer cell lectin-like receptor subfamily C, member 1 Klrc1 -3.34 7.13E-05 0.0034
predicted gene, 42362 Gm42362 -3.49 0.0017 0.022
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Table 6. Leading edge genes in DIO vs. HCCR groups contributing to enrichment in mTOR 
signaling gene sets 
Score
FASLG Fas ligand [Source:HGNC Symbol;Acc:HGNC:11936] -0.2462296
SLA Src like adaptor [Source:HGNC Symbol;Acc:HGNC:10902] -0.2443126
FGL2 fibrinogen like 2 [Source:HGNC Symbol;Acc:HGNC:3696] -0.2381766
LCK LCK proto-oncogene, Src family tyrosine kinase [Source:HGNC Symbol;Acc:HGNC:6524] -0.2222347
CXCR4 C-X-C motif chemokine receptor 4 [Source:HGNC Symbol;Acc:HGNC:2561] -0.2013458
VAV3 vav guanine nucleotide exchange factor 3 [Source:HGNC Symbol;Acc:HGNC:12659] -0.1944445
TIAM1 T cell lymphoma invasion and metastasis 1 [Source:HGNC Symbol;Acc:HGNC:11805] -0.1751118
SLC7A11 solute carrier family 7 member 11 [Source:HGNC Symbol;Acc:HGNC:11059] -0.1685393
RPS6KA1 ribosomal protein S6 kinase A1 [Source:HGNC Symbol;Acc:HGNC:10430] -0.1615428
TFRC transferrin receptor [Source:HGNC Symbol;Acc:HGNC:11763] -0.1612434
ITGB2 integrin subunit beta 2 [Source:HGNC Symbol;Acc:HGNC:6155] -0.1608516
GBE1 1,4-alpha-glucan branching enzyme 1 [Source:HGNC Symbol;Acc:HGNC:4180] -0.1533082
CORO1A coronin 1A [Source:HGNC Symbol;Acc:HGNC:2252] -0.1472521
SYTL2 synaptotagmin like 2 [Source:HGNC Symbol;Acc:HGNC:15585] -0.1201656
CFP complement factor properdin [Source:HGNC Symbol;Acc:HGNC:8864] -0.1089074
GRK2 G protein-coupled receptor kinase 2 [Source:HGNC Symbol;Acc:HGNC:289] -0.0991553
DHFR dihydrofolate reductase [Source:HGNC Symbol;Acc:HGNC:2861] -0.0955414
CTSC cathepsin C [Source:HGNC Symbol;Acc:HGNC:2528] -0.0939144
DAPP1 dual adaptor of phosphotyrosine and 3-phosphoinositides 1 [Source:HGNC Symbol;Acc:HGNC:16500] -0.0930259
PRKCB protein kinase C beta [Source:HGNC Symbol;Acc:HGNC:9395] -0.088084
RRM2 ribonucleotide reductase regulatory subunit M2 [Source:HGNC Symbol;Acc:HGNC:10452] -0.0837446
RIPK1 receptor interacting serine/threonine kinase 1 [Source:HGNC Symbol;Acc:HGNC:10019] -0.0818542
UCHL5 ubiquitin C-terminal hydrolase L5 [Source:HGNC Symbol;Acc:HGNC:19678] -0.075672
NFIL3 nuclear factor, interleukin 3 regulated [Source:HGNC Symbol;Acc:HGNC:7787] -0.0739342
UFM1 ubiquitin fold modifier 1 [Source:HGNC Symbol;Acc:HGNC:20597] -0.0732693
MTHFD2L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2 like [Source:HGNC Symbol;Acc:HGNC:31865] -0.0727752
PLA2G12A phospholipase A2 group XIIA [Source:HGNC Symbol;Acc:HGNC:18554] -0.065741
GLRX glutaredoxin [Source:HGNC Symbol;Acc:HGNC:4330] -0.064695
CAMK4 calcium/calmodulin dependent protein kinase IV [Source:HGNC Symbol;Acc:HGNC:1464] -0.0637717
SKAP2 src kinase associated phosphoprotein 2 [Source:HGNC Symbol;Acc:HGNC:15687] -0.0631477
INSIG1 insulin induced gene 1 [Source:HGNC Symbol;Acc:HGNC:6083] -0.0630068
SLC6A6 solute carrier family 6 member 6 [Source:HGNC Symbol;Acc:HGNC:11052] -0.0618664
GLA galactosidase alpha [Source:HGNC Symbol;Acc:HGNC:4296] -0.0598024
PPP1R15A protein phosphatase 1 regulatory subunit 15A [Source:HGNC Symbol;Acc:HGNC:14375] -0.0595133
MKNK1 MAP kinase interacting serine/threonine kinase 1 [Source:HGNC Symbol;Acc:HGNC:7110] -0.0591016
PPA1 pyrophosphatase (inorganic) 1 [Source:HGNC Symbol;Acc:HGNC:9226] -0.0582892
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase [Source:HGNC Symbol;Acc:HGNC:5006] -0.0578481
SC5D sterol-C5-desaturase [Source:HGNC Symbol;Acc:HGNC:10547] -0.0547113
TMEM97 transmembrane protein 97 [Source:HGNC Symbol;Acc:HGNC:28106] -0.0523583
LGMN legumain [Source:HGNC Symbol;Acc:HGNC:9472] -0.0512434
NUFIP1 nuclear FMR1 interacting protein 1 [Source:HGNC Symbol;Acc:HGNC:8057] -0.0500715
IL4 interleukin 4 [Source:HGNC Symbol;Acc:HGNC:6014] -0.0485619
NFKBIB NFKB inhibitor beta [Source:HGNC Symbol;Acc:HGNC:7798] -0.0485524
GMPS guanine monophosphate synthase [Source:HGNC Symbol;Acc:HGNC:4378] -0.0480232
HPRT1 hypoxanthine phosphoribosyltransferase 1 [Source:HGNC Symbol;Acc:HGNC:5157] -0.0471522
PDK1 pyruvate dehydrogenase kinase 1 [Source:HGNC Symbol;Acc:HGNC:8809] -0.0466781
THEM4 thioesterase superfamily member 4 [Source:HGNC Symbol;Acc:HGNC:17947] -0.0464022
MAPK8 mitogen-activated protein kinase 8 [Source:HGNC Symbol;Acc:HGNC:6881] -0.0455124
CCNG1 cyclin G1 [Source:HGNC Symbol;Acc:HGNC:1592] -0.0454851
PNO1 partner of NOB1 homolog [Source:HGNC Symbol;Acc:HGNC:32790] -0.0431167
GTF2H1 general transcription factor IIH subunit 1 [Source:HGNC Symbol;Acc:HGNC:4655] -0.042118
PSMC4 proteasome 26S subunit, ATPase 4 [Source:HGNC Symbol;Acc:HGNC:9551] -0.0417138
PSMG1 proteasome assembly chaperone 1 [Source:HGNC Symbol;Acc:HGNC:3043] -0.0409973
RRP9 ribosomal RNA processing 9, U3 small nucleolar RNA binding protein [Source:HGNC Symbol;Acc:HGNC:16829] -0.0404222






IMMT inner membrane mitochondrial protein [Source:HGNC Symbol;Acc:HGNC:6047] -0.038824
NAMPT nicotinamide phosphoribosyltransferase [Source:HGNC Symbol;Acc:HGNC:30092] -0.0386638
IFRD1 interferon related developmental regulator 1 [Source:HGNC Symbol;Acc:HGNC:5456] -0.038385
CYP51A1 cytochrome P450 family 51 subfamily A member 1 [Source:HGNC Symbol;Acc:HGNC:2649] -0.0378651
STARD4 StAR related lipid transfer domain containing 4 [Source:HGNC Symbol;Acc:HGNC:18058] -0.0375368
PSMC6 proteasome 26S subunit, ATPase 6 [Source:HGNC Symbol;Acc:HGNC:9553] -0.0372621
NFYC nuclear transcription factor Y subunit gamma [Source:HGNC Symbol;Acc:HGNC:7806] -0.0351893
TUBA4A tubulin alpha 4a [Source:HGNC Symbol;Acc:HGNC:12407] -0.0351514
M6PR mannose-6-phosphate receptor, cation dependent [Source:HGNC Symbol;Acc:HGNC:6752] -0.0344971
DDX39A DExD-box helicase 39A [Source:HGNC Symbol;Acc:HGNC:17821] -0.0340657
BHLHE40 basic helix-loop-helix family member e40 [Source:HGNC Symbol;Acc:HGNC:1046] -0.0338917
G6PD glucose-6-phosphate dehydrogenase [Source:HGNC Symbol;Acc:HGNC:4057] -0.0323162
ETF1 eukaryotic translation termination factor 1 [Source:HGNC Symbol;Acc:HGNC:3477] -0.0313713
CCNF cyclin F [Source:HGNC Symbol;Acc:HGNC:1591] -0.0309685
TXNRD1 thioredoxin reductase 1 [Source:HGNC Symbol;Acc:HGNC:12437] -0.0309159
ELOVL6 ELOVL fatty acid elongase 6 [Source:HGNC Symbol;Acc:HGNC:15829] -0.028821
EBP EBP cholestenol delta-isomerase [Source:HGNC Symbol;Acc:HGNC:3133] -0.0285112
TOMM40 translocase of outer mitochondrial membrane 40 [Source:HGNC Symbol;Acc:HGNC:18001] -0.0283932
TUBG1 tubulin gamma 1 [Source:HGNC Symbol;Acc:HGNC:12417] -0.0278695
ACTR3 actin related protein 3 [Source:HGNC Symbol;Acc:HGNC:170] -0.0276972
GOT1 glutamic-oxaloacetic transaminase 1 [Source:HGNC Symbol;Acc:HGNC:4432] -0.0267994
PITPNB phosphatidylinositol transfer protein beta [Source:HGNC Symbol;Acc:HGNC:9002] -0.0267504
PSMD12 proteasome 26S subunit, non-ATPase 12 [Source:HGNC Symbol;Acc:HGNC:9557] -0.0266193
MCM4 minichromosome maintenance complex component 4 [Source:HGNC Symbol;Acc:HGNC:6947] -0.0262224
WARS tryptophanyl-tRNA synthetase [Source:HGNC Symbol;Acc:HGNC:12729] -0.0257211
COPS5 COP9 signalosome subunit 5 [Source:HGNC Symbol;Acc:HGNC:2240] -0.0256744
SQLE squalene epoxidase [Source:HGNC Symbol;Acc:HGNC:11279] -0.0256567
FAM129A family with sequence similarity 129 member A [Source:HGNC Symbol;Acc:HGNC:16784] -0.0256365
